Introduction
 
In the previous two blogs, we discussed pulsed electromagnetic field therapy (December 17, 2025) and acupuncture (November 15, 2025) as potential treatments for osteoarthritis (OA), and we cited two comparative studies reporting that extracorporeal shock wave therapy (ESWT) was more effective than both modalities (1,2). However, the small sample sizes of these trials, together with conclusions based solely on meta-analyses, make such claims potentially tenuous. Nevertheless, it remains valuable to examine ESWT in greater detail—specifically, to review the clinical evidence supporting its effectiveness and to discuss its proposed mechanisms of action. We also review the range of ESWT devices currently available on the market for both medical professionals and consumers.
 

Two types of shock waves
 
In ESWT, a focused shock wave is a high-pressure, nonlinear acoustic pulse characterized by an extremely rapid rise time (<10 ns), a high positive peak pressure (10–100 MPa), short pulse duration (~1–10 µs), a subsequent tensile (negative-pressure) phase, and a broad frequency spectrum ranging from kilohertz to megahertz. In most focused ESWT devices used in medical practice, shock waves are generated using one of three physical principles: electrohydraulic (spark-gap), electromagnetic, or piezoelectric mechanisms (3).
 
By contrast, some devices produce so-called radial shock waves, which are generated by the impact of a ballistic projectile and result in radially dispersing pressure waves with maximal pressure at the applicator surface rather than at depth. From a physical standpoint, these waves are closer to pressure pulses than to true shock waves, and radial devices are therefore not generally considered genuine shock wave generators. The practical implications of this distinction will be discussed further below when device characteristics are examined.

ESWT device characteristics
 
Five parameters are commonly used to characterize an ESWT device:

1. Energy Flux Density (EFD) is the most important parameter. It represents the amount of energy delivered per unit area per pulse, measured in mJ/mm2. Devices are typically classified as low-, medium-, or high-energy, as shown below.
 
                                               EFD (mJ/mm²)        Classification
                                                   < 0.08                            Low energy
                                                    0.08–0.28                     Medium energy
                                                    > 0.28                             High energy

2. Peak pressure includes both the positive (P⁺) and negative (P⁻) pressure components. P⁺ reflects   the compressive force and is important for mechanotransduction, whereas P⁻ produces cavitation and plays a key role in biological signaling as well as in assessing potential tissue risk. Typical P⁺ values for focused ESWT devices range from 20 to 100 MPa, whereas radial devices operate at much lower pressures, typically 1–10 MPa. That said, peak pressure alone can be misleading because it does not account for pulse duration or focal size.
 
3. Pulse rise time and duration also influence biological effects. In most ESWT systems, rise times are less than 10 ns and pulse durations range from 1 to 10 μs. Shorter pulses tend to deliver high instantaneous mechanical stress, minimize thermal effects, and preferentially activate mechanical signaling pathways.
 
4. Pulse repetition frequency for most devices ranges from 1 to 8 Hz. In clinical practice, the total number of pulses per session vary from 500 to 3000, depending on the indication. While pulse repetition frequency does not alter the EFD, it directly affect overall treatment duration.
 
5. Focal volume and penetration depth represent a major distinction between focused and radial ESWT. In focused ESWT, energy is concentrated within an ellipsoid focal zone located at depths of approximately 10-60 mm. In contrast, radial ESWT delivers its highest energy at the skin surface, with rapid attenuation such that penetration rarely exceeds 1–2 cm. Focused ESWT is therefore often preferred for osteoarthritis—particularly knee osteoarthritis—where therapeutic targets may include deeper periarticular tissues, entheses, and subchondral bone.

Comparing ESWT devices
 
When comparing ESWT devices, the most important features to consider are the type of shock wave (focused vs. radial), the EFD at the focal point (mJ/mm²), and the focal depth and volume. Equally important are pulse reproducibility and whether device parameters are measured and reported in accordance with IEC standards.
 
Clinical studies using ESWT, should at a minimum, specify the EFD and the total pulse count delivered during treatment.
 
Numerous educational videos are available online explaining the differences and clinical roles of focused and radial ESWT. Two accessible examples that provide a useful overview of both techniques—and how they may complement one another—include:

​Clinical Proofs that ESWT is effective in the treatment of knee osteoarthritis

​Multiple randomized controlled trials and meta-analyses (4–8) consistently show that ESWT reduces pain and improves function in patients with knee osteoarthritis when compared with sham treatment or other conservative interventions. In many studies, these benefits persist for weeks to several months. Several trials also demonstrate a dose–response relationship, with medium-energy protocols producing superior clinical outcomes compared with low-energy treatments (9–11). In addition, focused ESWT—which is capable of reaching deeper structures such as subchondral bone—may provide better joint-related outcomes than radial devices (12).
 
A simplified summary of reported EFD ranges and associated biological effects is shown below:

Importantly, the beneficial effects of ESWT may extend even to patients with advanced disease. A recent study by CP, K. et al. (13) reported clinical improvements in patients with Kellgren–Lawrence (K–L) grade 4 osteoarthritis. Similarly, a randomized clinical trial by Choi, I.J. et al. (14) demonstrated reductions in suprapatellar effusion and improvements in inflammatory symptoms following ESWT, providing in vivo support for its anti-inflammatory effects.
 
Evidence for true disease-modifying effects—such as structural preservation of articular cartilage—remains mixed and incomplete. Preclinical studies and mechanistic human data suggest that ESWT can stimulate subchondral bone remodeling and activate anabolic signaling pathways in chondrocytes, which are biologically plausible disease-modifying mechanisms. However, robust long-term randomized controlled trials incorporating quantitative MRI endpoints or histological evidence of slowed cartilage loss are still scarce. Notably, at least one randomized controlled trial (15) reported potential adverse effects on cartilage under a specific low-dose protocol, highlighting that not all ESWT treatment regimens are necessarily structurally protective.
 
In summary, the evidence supporting symptomatic relief from ESWT in knee osteoarthritis is strong, whereas convincing proof of durable cartilage preservation in humans will require more standardized, long-term imaging-based clinical trials.


Comparing ESWT with other therapies for osteoarthritis
 
A systematic review and meta-analysis by Chen, L. et al. (16) compared ESWT with a wide range of treatment modalities across different forms of osteoarthritis. The analysis focused specifically on pain reduction and functional improvement. The overall findings are summarized in the table below.

“+” indicates results favoring ESWT over the comparator; “–” indicates comparable or superior results for the comparator; “?” indicates insufficient or inconsistent evidence. HA: hyaluronic acid; PRP: Platelet Rich Plasma
 
These findings can be contrasted with the results reported by Cao, S. et al. (2), who restricted their analysis to non-pharmacological interventions for knee osteoarthritis—a study discussed previously in the November 15, 2025 blog on acupuncture for knee OA. Selected results from that analysis are reproduced below for comparison.

Efficacy rankings based on the Visual Analog Scale (VAS) pain scores:

shock wave therapy > needle-knife (acupotomy) > laser therapy > acupuncture > ultrasound > exercise > transcutaneous electrical nerve stimulation
 
Efficacy rankings based on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) subscales:

• Pain: shock wave therapy > needle-knife (acupotomy) > laser therapy > acupuncture > exercise > transcutaneous electrical nerve stimulation > ultrasound

 

• Stiffness: laser therapy > exercise > shock wave therapy > acupuncture > needle-knife > ultrasound > transcutaneous electrical nerve stimulation

 

• Physical function: shock wave therapy > laser therapy > needle-knife > acupuncture > ultrasound > transcutaneous electrical nerve stimulation > exercise

 
The two datasets overlap in their comparison of ESWT with ultrasound and acupotomy (needle-knife). For ultrasound, the findings are consistent: ESWT outperformed ultrasound in both analyses. In contrast, the results for acupotomy diverge. Cao, S. et al. reported that ESWT was superior for both pain reduction and functional improvement, whereas Chen, L. et al. found acupotomy to perform as well as—or better than—ESWT in these same outcomes.
 
These discrepancies highlight the need for well-designed, head-to-head randomized controlled trials directly comparing treatment modalities. Meta-analyses based on small, heterogeneous trials with variable protocols and controls have inherent limitations and should be interpreted with appropriate caution.


ESWT Mechanism of Action
 
Clinical studies indicate that ESWT typically employs low- to medium-energy flux densities to elicit beneficial biological responses in osteoarthritis without causing tissue damage. How this mechanical energy interacts with cells and biomolecules—and which molecular pathways translate these interactions into therapeutic effects—is therefore of considerable interest. A clearer understanding of these mechanisms can inform more rational ESWT protocol design tailored to specific patient populations.
 
ESWT delivers very high peak stresses with an extremely rapid rise time to cellular structures, particularly cell membranes. The resulting steep spatial pressure gradients, together with cavitation effects, activate mechanotransduction pathways, many of which have been identified over the past two decades. Most mechanistic studies to date have been conducted in animal models or in isolated cells and tissues derived from cartilage and subchondral bone.

Dose effect, angiogenesis, cartilage/subchondral bone remodeling
 
A clear dose-dependent effect of ESWT was demonstrated by Wang, C.-J. et al. (17) using a surgically induced knee osteoarthritis (KOA) rat model. In this study, an optimal dose of 800 pulses delivered at an energy flux density of 0.22 mJ/mm², administered once or twice weekly, was sufficient to inhibit deterioration of both articular cartilage and subchondral bone in periarticular regions. These effects were assessed using X-ray imaging, histomorphological analysis, and immunohistochemistry.
Articular cartilage integrity was evaluated by immunostaining for collagen type II and matrix metalloproteinase-13 (MMP-13), whereas subchondral bone remodeling and angiogenesis were assessed through immunostaining of von Willebrand factor (vWF), vascular endothelial growth factor (VEGF), bone morphogenetic protein-2 (BMP-2), and osteocalcin.
 
The main biological effects observed in response to ESWT can be summarized as follows:

• Cartilage effects:
  ESWT → ↑ collagen type II, ↓ MMP-13 → improved cartilage integrity
• Subchondral bone and angiogenesis:
  ESWT → ↑ vWF, ↑ VEGF, ↑ BMP-2, ↑ osteocalcin → enhanced angiogenesis and subchondral bone remodeling

 
Effect on bone homeostasis
 
Direct effects of ESWT on bone homeostasis—specifically on osteoblast and osteoclast differentiation—have been reported by Li, B. et al. (18) and Chen, B. et al. (19). Using cultured rabbit bone marrow–derived stem cells, these authors demonstrated that ESWT promotes differentiation toward osteoblasts, as shown by classical histochemical staining and mRNA profiling of osteogenesis-related markers, including alkaline phosphatase (ALP), osteocalcin (OCN), osteoprotegerin (OPG), and runt-related transcription factor 2 (Runx2).
 
In vivo, using a rabbit model of osteoporosis, ESWT increased trabecular bone volume, number, and thickness, while reducing trabecular separation in the femur when compared with untreated controls.
 
To examine effects on osteoclastogenesis, immortalized mouse macrophage RAW264.7 cells induced with receptor activator of nuclear factor κB ligand (RANKL) and macrophage colony-stimulating factor (M-CSF) were used as a model system. In this context, ESWT inhibited differentiation into osteoclasts, as determined by histochemical staining and reduced mRNA expression of two key osteoclast markers, cathepsin K and dendritic cell–specific transmembrane protein (DC-STAMP). ESWT also suppressed cell proliferation and reduced expression of NFATc1 as well as p65, a subunit of the NF-κB transcriptional complex, indicating that inhibition of NF-κB signaling underlies the anti-osteoclastogenic effect. Consistent with these findings, ESWT increased trabecular bone volume, number, and thickness and decreased trabecular separation in mouse femora.
 
The principal cellular effects of ESWT on bone homeostasis can be summarized as follows:

• Osteoblastogenesis:
  ESWT → ↑ ALP, ↑ OCN, ↑ OPG, ↑ Runx2 → increased osteoblast differentiation
• Osteoclastogenesis:
  ESWT → ↓ cathepsin K, ↓ DC-STAMP → reduced osteoclast differentiation
• Cell proliferation signaling:
  ESWT → ↓ NFATc1, ↓ p65 → ↓ NF-κB signaling → reduced cell proliferation

 
Zhao, Z. et al. (20) identified an additional molecular pathway mediating the effects of ESWT in subchondral bone–derived stem cells. Using primary human stem cells isolated from patients with knee osteoarthritis, the authors showed that ESWT increased colony-forming capacity in a dose-dependent manner. This effect was driven by enhanced proliferation without measurable changes in apoptosis. Although no significant effect on osteogenic differentiation was observed, ESWT strongly suppressed adipogenic differentiation and modestly enhanced chondrogenic differentiation. Expression of cartilage-related markers, including collagen type II and proteoglycans, was consistently higher than in untreated controls.
 
Notably, these phenotypic changes were associated with increased expression of the mechanosensitive co-transcriptional regulators YAP and TAZ and their translocation into the nucleus. YAP/TAZ signaling is well recognized for its role in mechanotransduction, organ size regulation, tissue regeneration, wound healing, and stem cell maintenance.
 
These effects may be summarized schematically as:

• Stem cell fate modulation:
  ESWT → actin stress fiber remodeling → YAP/TAZ nuclear localization → ↑ stem cell proliferation → ↓ adipogenesis, ↑ chondrogenesis → ↑ collagen II, ↑ proteoglycans

 
Finally, it is worth noting the apparent discrepancy between the findings of Li, B. et al. (18), who observed ESWT-induced osteogenic differentiation in healthy rabbit bone marrow stem cells, and those of Zhao, Z. et al. (20), who did not detect osteogenic differentiation in subchondral bone stem cells derived from patients with knee osteoarthritis. Differences in species, tissue origin, and disease state may plausibly account for this divergence and underscore the complexity of translating mechanistic findings across experimental models.

Apoptosis and autophagy
 
The effects of ESWT on apoptosis and autophagy have been demonstrated in a cellular model of osteoarthritis using primary rat chondrocytes stimulated with interleukin-1β (IL-1β) (21). This model was validated by showing that IL-1β downregulated collagen type II expression, a hallmark of cartilage degeneration, and that ESWT was able to reverse this effect.
 
The authors further demonstrated that ESWT inhibited IL-1β–induced apoptosis, as assessed by Annexin V–FITC/propidium iodide flow cytometry. In contrast, autophagy was enhanced, as evidenced by changes in both mRNA and protein expression of key autophagy markers, including Beclin-1, Atg5, LC3B, and p62. This dual effect—suppression of apoptosis alongside activation of autophagy—is consistent with the overall protective role of ESWT in cartilage degeneration.
 
The anti-apoptotic effect of ESWT also aligns with earlier findings reported by Zhao, Z. et al. (22), who observed reduced nitric oxide (NO) levels in the knee joint and synovial fluid following ESWT in a rabbit model of knee osteoarthritis. Given the established pro-apoptotic role of NO in chondrocytes, this observation provides additional mechanistic support.
 
The key molecular effects can be summarized as follows:

• Apoptosis:
  ESWT → ↓ NO → reduced apoptosis
• Autophagy:
  ESWT → ↑ Beclin-1, ↑ Atg5, ↑ LC3B, ↓ p62 → enhanced autophagy

 
Reactive oxygen species (ROS) signaling
 
Building on earlier reports of increased intracellular reactive oxygen species (ROS) following ESWT, Shen, P.-C. et al. (23) used primary porcine chondrocytes to characterize this response in greater detail. They demonstrated a dose-dependent but transient increase in ROS levels, peaking at approximately 10 minutes after treatment and returning to baseline within one hour. The authors identified xanthine oxidase as the primary source of ROS generation.
 
Importantly, this transient ROS burst was followed by increased extracellular matrix (ECM) synthesis, without adverse effects on cell viability or proliferation. Enhanced ECM production was accompanied by increased phosphorylation of p38 mitogen-activated protein kinase (MAPK) and ERK1/2, as well as nuclear translocation of nuclear factor erythroid 2–related factor 2 (Nrf2), a key transcription factor regulating cellular antioxidant and detoxification pathways.
These findings suggest that a brief, well-controlled ROS signal acts as a beneficial second messenger rather than a source of oxidative damage in the context of ESWT.
 
The principal signaling events can be summarized as follows:

• ECM synthesis:
  ESWT → transient ROS ↑ → increased ECM production
• MAPK signaling:
  ESWT → transient ROS ↑ → ↑ p-ERK1/2, ↑ p-p38 MAPK
• Antioxidant response:
  ESWT → transient ROS ↑ → Nrf2 nuclear translocation → increased antioxidant production

 
1a,25-Dihydroxy vitamin D3 rapid signaling pathway
 
Using a surgically induced rat model of knee osteoarthritis combined with a proteomic approach, Hsu, S.-L. et al. (24) showed that ESWT treatment (800 impulses delivered at 0.18 mJ/mm² and 4 Hz) optimally induced expression of protein disulfide isomerase–associated 3 (Pdia-3) within two weeks of treatment. Pdia-3 has been implicated as a membrane-associated co-receptor for 1α,25-dihydroxyvitamin D₃ (1α,25(OH)₂D₃, calcitriol), which, together with the classical nuclear vitamin D receptor, mediates rapid, non-genomic signaling.
 
This rapid signaling pathway is known to activate voltage-gated Ca²⁺ channels, increase intracellular Ca²⁺ flux, and trigger several downstream kinase cascades (25). Activation of the 1α,25-dihydroxyvitamin D₃ rapid signaling pathway in ESWT-treated articular cartilage and subchondral bone was supported by increased expression of four downstream effectors—ERK1, osteoprotegerin (OPG), alkaline phosphatase (ALP), and matrix metalloproteinase-13 (MMP-13)—all of which are associated with bone remodeling and formation.
 
The proposed signaling cascade can be summarized as follows:

• Vitamin D–related rapid signaling:
  ESWT → ↑ Pdia-3 → activation of 1α,25-dihydroxyvitamin D₃ rapid signaling → ↑ ERK1, ↑ OPG, ↑ ALP, ↑ MMP-13 → enhanced bone formation

 
Vitamin D–related signaling is increasingly recognized as relevant in osteoarthritis because of its central role in regulating calcium homeostasis, bone turnover, and chondrocyte function. Articular cartilage and subchondral bone both express components of the vitamin D signaling machinery, and disturbances in this pathway have been associated with altered bone remodeling, cartilage degradation, and OA progression. Beyond its classical genomic actions, rapid, non-genomic vitamin D signaling influences mechanosensitive pathways, intracellular calcium flux, and kinase activation—processes that are highly responsive to mechanical stimuli. The ability of ESWT to engage this rapid signaling axis therefore provides a plausible mechanistic link between mechanical energy delivery and coordinated biological responses in cartilage and subchondral bone, particularly in the mechanically driven environment of osteoarthritis.

Wnt5a/Ca2+ signaling pathway
 
Evidence for activation of the Wnt5a/Ca²⁺ signaling pathway by ESWT was reported by Yu, L. et al. (26) using both an in vivo chemically induced rat model of knee osteoarthritis and in vitro experiments with bone marrow–derived mesenchymal stem cells (BMMSCs) isolated from rat femur and tibia.
 
Immunostaining of subchondral bone plates from KOA rats treated with radial ESWT (1 bar, 6 Hz, 800 pulses) revealed higher Wnt5a expression compared with both sham-treated KOA rats and normal controls. This increased expression correlated with improved histological morphology, reflected by lower Mankin scores, relative to sham-treated animals.
 
In vitro, BMMSCs exposed to ESWT exhibited a time-dependent increase in Wnt5a expression. Levels peaked approximately 30 minutes after treatment and gradually declined with longer exposure times of up to 3 hours. Quantitative RT-PCR indicated that optimal Wnt5a induction occurred at 0.6 bar with a 30-minute exposure. ESWT also induced expression of several downstream components of the Wnt5a/Ca²⁺ pathway, including calcium/calmodulin-dependent protein kinase II (CaMKII), phospholipase C (PLC), and protein kinase C (PKC), with variable temporal patterns over a 3-hour time course.
 
The proposed signaling sequence may be summarized as:

• Non-canonical Wnt signaling:
  ESWT → Ca²⁺ influx → Wnt5a activation → PLC / PKC / CaMKII signaling → effects on bone and cartilage remodeling (?)

 
The authors attributed the observed improvements in cartilage and subchondral bone morphology following ESWT to activation of the Wnt5a/Ca²⁺ signaling pathway. However, such a conclusion should be interpreted with caution. Wnt5a is a pleiotropic signaling molecule involved in a wide range of biological processes, including embryonic development, inflammation, and cancer. Notably, Wnt5a has also been implicated in osteoarthritis pathogenesis, where it may promote cartilage degradation and inflammation by activating catabolic pathways, increasing matrix-degrading enzymes such as MMPs, and disrupting joint homeostasis (27,28).
 
Taken together, these findings suggest that while ESWT can modulate Wnt5a/Ca²⁺ signaling, the net biological outcome is likely to be highly context-dependent, influenced by dose, timing, tissue state, and disease severity.

 
Mechanistic Summary
 
Taken together, the available mechanistic evidence suggests that ESWT acts as a pleiotropic biomechanical stimulus that engages multiple, interconnected signaling pathways in cartilage and subchondral bone. At low to medium energy flux densities, ESWT delivers rapid, high-peak mechanical stress that activates mechanotransduction at the cell membrane, leading to downstream modulation of inflammation, apoptosis, autophagy, and tissue remodeling. ESWT promotes angiogenesis and subchondral bone remodeling, enhances osteoblast differentiation while suppressing osteoclastogenesis, and shifts stem cell fate away from adipogenesis toward chondrogenesis. Transient increases in reactive oxygen species function as second messengers that activate MAPK and Nrf2-dependent antioxidant pathways, supporting extracellular matrix synthesis without compromising cell viability. ESWT also engages rapid, non-genomic vitamin D signaling through Pdia-3, linking mechanical stimulation to calcium flux and bone-forming cascades. Finally, modulation of non-canonical Wnt5a/Ca²⁺ signaling highlights the context-dependent nature of ESWT responses, emphasizing the importance of dose, timing, and disease state. Collectively, these mechanisms provide a biologically plausible framework for the clinical benefits of ESWT in knee osteoarthritis while underscoring the need for carefully optimized treatment protocols.

Common commercially available ESWT devices
 
Commercially available ESWT systems can be broadly divided into two categories: clinical-grade devices intended for use by medical professionals and devices marketed directly to consumers for general wellness applications.
 
Clinical ESWT Devices (Professional Use)
 
Clinical ESWT devices are designed to deliver precisely controlled energy flux densities (EFDs) and pulse frequencies. These systems are capable of generating substantial mechanical forces that can modulate tissue physiology, including effects on subchondral bone remodeling, angiogenesis, and chondrocyte mechanotransduction. As such, their safe and effective use requires appropriate training in dosimetry, anatomical targeting, and patient selection.
 
Improper self-application—particularly without imaging guidance or professional assessment—may result in subtherapeutic treatment or, in some cases, tissue injury. For this reason, focused ESWT devices operating at medium to high EFDs are typically restricted to clinical settings.
 
It is also important to note that there are currently no FDA-approved focused ESWT devices intended for direct consumer or self-use, especially at the energy levels required to reach deep joint tissues such as the knee. Focused shockwave systems are generally regulated as prescription-only medical devices due to safety considerations and the need for clinical oversight. Many are used off-label for osteoarthritis based on clinician judgment and emerging evidence rather than explicit FDA indications.
 
Examples of focused and radial ESWT devices commonly found in outpatient physical therapy, sports medicine, and rehabilitation clinics are listed below. Device parameters—such as pressure or EFD, pulse frequency, and applicator size—are adjustable and tailored to the clinical indication and patient tolerance.

Focused type:
OrthoGold 100 (MTS)
Endopuls FSWT (Enraf-Nonius) 
PiezoWave2® (Richard Wolf)
DolorClast® Focused Shock Waves (EMS Electro Medical System SA)
Emfocus (GZ MTS Electronics Co., Ltd.): Electromagnetic focused ESWT
 
Radial type:
Endopuls 811 (Enraf-Nonius) 
DolorClast® Radial Shock Waves (EMS Electro Medical System SA)
Softshock 2.0 (Medray Laser & Technology): Radial ESWT device.
Z Wave® Q (Zimmer MedizinSystems): Radial ESWT device.
Klinogicare Shockwave Storm Radial (Klinogicare)
PHS Radial Shockwave, PHS6B (PHSDME)
AWT Radial Shockwave Therapy (Hedone/clinics)
INWAVE Radial Shockwave (INWAVE Medical)
MTS SWT9 Radial ESWT System (GZ MTS Electronics Co., Ltd.)
Modus ESWT® Radial Shockwave (Refizo)
 
An example of a modular mixed-use type
Duolith® SD1 Ultra (Storz Medical): A modular system for both focused and radial ESWT with optional Ultrasound diagnostics.

Consumer-Targeted “Shockwave” Devices
 
A separate category includes devices marketed directly to consumers for general wellness, pain relief, or soft-tissue massage. While some of these products advertise “shockwave” technology and adjustable energy output, they are not FDA-cleared for specific medical indications such as osteoarthritis or tendinopathy.
 
Reported energy outputs are typically not standardized to clinical EFD measurements, are rarely independently verified, and lack validation in peer-reviewed clinical trials. These devices generally deliver lower, more variable energy levels rather than those of true therapeutic shock waves. Consequently, they should not be considered equivalent to clinical ESWT systems and should be used with caution.
 
Examples of consumer-market devices include:
 
Shape Tactics Radial Shockwave Therapy Device (Cavitation Machines)
PSP20 Extracorporeal Shock Wave Therapy Machine (Pervita Medical)
Q60A Extracorporeal Shock Wave Therapy (Sheyera)
MODOY ESWT02 (MODOY)
 
Finding a provider of shock wave therapy
 
Primary care doctors, orthopedic surgeons, and physical therapists can offer reliable information or references. Additional resources and platforms include:
 
Shockwave Provider Directories
 
Several private or industry-associated directories list clinics or providers offering shockwave treatments:

• Shockwave Center of America— lists various clinics, including PT practices, chiropractors, and other providers that offer shockwave therapy in different U.S. regions. You can search by location to find providers
• Shockwave Near Me — a web directory where you can search for local shockwave therapy providers and view profiles and reviews.
• Medical Shockwave Institute — searchable list of certified radial and focal shockwave providers.

 
These directories are not exclusively physical therapists, but they include PTs alongside other clinicians.
 
Vendor-Specific “Find a Provider” Tools
 
Some shockwave device manufacturers maintain provider locators through their own channels. For example, SoftWave Clinics site lets patients locate clinics (including physical therapy clinics) that use its technology. These are useful if you know the brand of devices being used in your area.
 
Local Clinic Search and Therapy Networks
 
You can also use generalized health provider search services (not specialty directories) to find ESWT-offering PT practices. For example, JustHealthy.com and similar “find a provider near me” services list nearby clinics offering shockwave therapy based on city or zip code.

​References

1. Pasin, T., & Dogruoz Karatekin, B. (2025). Comparison of Short-Term effects of extracorporeal shock wave therapy, Low-Level laser therapy and pulsed electromagnetic field therapy in knee osteoarthritis: A randomized controlled study. Journal of Clinical Medicine, 14(2), 594. https://doi.org/10.3390/jcm14020594
2. Cao, S., Zan, Q., Wang, B., Fan, X., Chen, Z., & Yan, F. (2024). Efficacy of non-pharmacological treatments for knee osteoarthritis: A systematic review and network meta-analysis. Heliyon, 10(17). DOI: 10.1016/j.heliyon.2024.e36682
3. Romeo, P., Lavanga, V., Pagani, D., & Sansone, V. (2013). Extracorporeal shock wave therapy in musculoskeletal disorders: a review. Medical Principles and Practice, 23(1), 7-13. https://doi.org/10.1159/000355472
4. Liao, P. C., Chou, S. H., & Shih, C. L. (2024). A systematic review of the use of shockwave therapy for knee osteoarthritis. Journal of Orthopaedics, 56, 18-25. doi: 10.1016/j.jor.2024.04.020
5. 2.Wen, T., Lu, W., Jin, H., Pan, L., Li, H., ... & Li, Y. (2024). The efficacy of extracorporeal shock wave therapy for knee osteoarthritis: an umbrella review. International Journal of Surgery, 110(4), 2389-2395. doi: 10.1097/JS9.0000000000001116
   
6. Liao, C. D., Huang, Y. Y., Chen, H. C., Liou, T. H., Lin, C. L., & Huang, S. W. (2022). Relative effect of extracorporeal shockwave therapy alone or in combination with noninjective treatments on pain and physical function in knee osteoarthritis: a network meta-analysis of randomized controlled trials. Biomedicines, 10(2), 306.  https://doi.org/10.3390/biomedicines10020306
7. Wang, Y. C., Huang, H. T., Huang, P. J., Liu, Z. M., & Shih, C. L. (2020). Efficacy and safety of extracorporeal shockwave therapy for treatment of knee osteoarthritis: a systematic review and meta-analysis. Pain Medicine, 21(4), 822-835. https://doi.org/10.1093/pm/pnz262
8. Avendano-Coy, J., Comino-Suarez, N., Grande-Munoz, J., Avendano-Lopez, C., & Gomez-Soriano, J. (2020). Extracorporeal shockwave therapy improves pain and function in subjects with knee osteoarthritis: A systematic review and meta-analysis of randomized clinical trials. International Journal of Surgery, 82, 64-75. https://doi.org/10.1016/j.ijsu.2020.07.055
9. 1.Kim, J. H., Kim, J. Y., Choi, C. M., Lee, J. K., Kee, H. S., Jung, K. I., & Yoon, S. R. (2015). The dose-related effects of extracorporeal shock wave therapy for knee osteoarthritis. Annals of rehabilitation medicine, 39(4), 616-623. DOI: https://doi.org/10.5535/arm.2015.39.4.616
   
10. Hammam, R. F., Kamel, R. M., Draz, A. H., Azzam, A. A., & El Kasem, S. T. A. (2020). Comparison of the effects between low-versus medium-energy radial extracorporeal shock wave therapy on knee osteoarthritis: a randomized controlled trial. Journal of Taibah University Medical Sciences, 15(3), 190-196. https://doi.org/10.1016/j.jtumed.2020.04.003
11. Zhang, Y. F., Yang, L. I. U., Shao-Wen, C. H. O. U., & Hao, W. E. N. G. (2020). Dose-related effects of radial extracorporeal shock wave therapy for knee osteoarthritis: A randomized controlled trial. Journal of Rehabilitation Medicine, 53(1), 2742. PMCID: PMC8772366
12. Ko, N. Y., Chang, C. N., Cheng, C. H., Yu, H. K., & Hu, G. C. (2022). Comparative effectiveness of focused extracorporeal versus radial extracorporeal shockwave therapy for knee osteoarthritis—Randomized controlled study. International Journal of Environmental Research and Public Health, 19(15), 9001.  https://doi.org/10.3390/ijerph19159001
13. Cp, A., Jayaraman, K., Babkair, R. A., Nuhmani, S., Nawed, A., Khan, M., & Alghadir, A. H. (2024). Effectiveness of extracorporeal shock wave therapy on functional ability in grade IV knee osteoarthritis–a randomized controlled trial. Scientific Reports, 14(1), 16530. https://doi.org/10.1038/s41598-024-67511-x
14. Choi, I. J., Jeon, J. H., Choi, W. H., & Yang, H. E. (2023). Effects of extracorporeal shockwave therapy for mild knee osteoarthritis: A pilot study. Medicine, 102(46), e36117. http://dx.doi.org/10.1097/MD.0000000000036117
15. Zhong, Z., Liu, B., Liu, G., Chen, J., Li, Y., Chen, J., ... & Hu, Y. (2019). A randomized controlled trial on the effects of low-dose extracorporeal shockwave therapy in patients with knee osteoarthritis. Archives of physical medicine and rehabilitation, 100(9), 1695-1702. https://doi.org/10.1016/j.apmr.2019.04.020
16. Chen, L., Ye, L., Liu, H., Yang, P., & Yang, B. (2020). Extracorporeal shock wave therapy for the treatment of osteoarthritis: a systematic review and meta‐analysis. BioMed research international, 2020(1), 1907821. doi: 10.1155/2020/1907821
17. Wang, C-J., Hsu, S. L., Weng, L. H., Sun, Y. C., & Wang, F. S. (2013). Extracorporeal shockwave therapy shows a number of treatment related chondroprotective effect in osteoarthritis of the knee in rats. BMC Musculoskeletal Disorders, 14(1), 44. https://doi.org/10.1186/1471-2474-14-44
18. Li, B., Wang, R., Huang, X., Ou, Y., Jia, Z., Lin, S., ... & Chen, B. (2021). Extracorporeal shock wave therapy promotes osteogenic differentiation in a rabbit osteoporosis model. Frontiers in endocrinology, 12, 627718.  https://doi.org/10.3389/fendo.2021.627718
19. Chen, B., Luo, Y., Zhang, Z., Lin, S., Wang, R., & Li, B. (2023). Extracorporeal shock wave therapy inhibits osteoclast differentiation by targeting NF-κB signaling pathway. Journal of Orthopaedic Surgery and Research, 18(1), 805. https://doi.org/10.1186/s13018-023-04166-w
20. Zhao, Z., Wang, Y., Wang, Q., Liang, J., Hu, W., Zhao, S., ... & Li, Z. (2021). Radial extracorporeal shockwave promotes subchondral bone stem/progenitor cell self-renewal by activating YAP/TAZ and facilitates cartilage repair in vivo. Stem cell research & therapy, 12(1), 19. https://doi.org/10.1186/s13287-020-02076-w
21. Wang, H., Tang, P., & Min, H. (2023). Extracorporeal shock wave protects chondrocytes against interleukin-1β-induced apoptosis and promotes autophagy in vitro. ScienceAsia, 49(1). doi: 10.2306/scienceasia1513-1874.2022.105
22. Zhao, Z., Ji, H., Jing, R., Liu, C., Wang, M., Zhai, L., ... & Xing, G. (2012). Extracorporeal shock-wave therapy reduces progression of knee osteoarthritis in rabbits by reducing nitric oxide level and chondrocyte apoptosis. Archives of orthopaedic and trauma surgery, 132(11), 1547-1553. https://doi.org/10.1007/s00402-012-1586-4
23. Shen, P. C., Chou, S. H., Lu, C. C., Huang, H. T., Chien, S. H., Huang, P. J., ... & Tien, Y. C. (2021). Shockwave treatment enhanced extracellular matrix production in articular chondrocytes through activation of the ROS/MAPK/Nrf2 signaling pathway. Cartilage, 13(2_suppl), 238S-253S. https://doi.org/10.1177/19476035211012465
24. Hsu, S.L., Cheng, J.H., Wang, C.J., Ko, J.Y., Hsu, C.H. (2017). Extracorporeal Shockwave Therapy Enhances Expression of Pdia-3 Which Is a Key Factor of the 1α,25-Dihydroxyvitamin D 3 Rapid Membrane Signaling Pathway in Treatment of Early Osteoarthritis of the Knee. International Journal of Medical Sciences, 14(12), 1220-1230. https://doi.org/10.7150/ijms.20303.
25. Boyan, B. D., Chen, J., & Schwartz, Z. (2012). Mechanism of Pdia3-dependent 1α, 25-dihydroxy vitamin D3 signaling in musculoskeletal cells. Steroids, 77(10), 892-896. https://doi.org/10.1016/j.steroids.2012.04.018
26. Yu, L., Liu, S., Zhao, Z., Xia, L., Zhang, H., Lou, J., ... & Xing, G. (2017). Extracorporeal shock wave rebuilt subchondral bone in vivo and activated Wnt5a/Ca2+ signaling in vitro. BioMed Research International, 2017(1), 1404650.  https://doi.org/10.1155/2017/1404650
27. Huang, G., Chubinskaya, S., Liao, W., & Loeser, R. F. (2017). Wnt5a induces catabolic signaling and matrix metalloproteinase production in human articular chondrocytes. Osteoarthritis and cartilage, 25(9), 1505-1515. https://doi.org/10.1016/j.joca.2017.05.018
28. Minghua, S., Jiwei, T., Lei, Z., Jizhou, Q., Zhiyuan, L., & Jiangang, C. (2024). Wnt5a manipulates the progression of osteoarthritis via MMP-13 dependent signaling pathway. Medicine, 103(50), e40676. doi: 10.1097/MD.0000000000040676

​Introduction
 
This is a continuation of our series on knee osteoarthritis. We discussed Pulsed Electromagnetic Field (PEMF) therapy and its applications in pain management in a blog post dated January 19, 2025. PEMF is known for its effectiveness in reducing pain and improving function in people with various musculoskeletal conditions, including knee osteoarthritis (knee OA). This position is supported by clinical data discussed in a health fact sheet produced by the National Center for Complementary and Integrative Health (NCCIH): “Magnets For Pain: What You Need To Know.” Here, we will update the information provided by the NCCIH on clinical effectiveness and mechanisms of action known to date, with a focus on knee osteoarthritis. Moreover, we will discuss commercial PEMF devices and associated protocols approved by the FDA specifically for the treatment of osteoarthritis, or approved only for the health and wellness consumer market but potentially applicable to osteoarthritis.

Clinical trials supporting effectiveness in osteoarthritis including knee osteoarthritis.
 
The cautious recommendation by the NCCIH that “Electromagnetic therapy may be a beneficial complementary therapy for treating osteoarthritis…” was based primarily on the meta-analysis of 12 clinical studies by Wu Z. et al. (2018) and the systematic review of 15 additional studies by Paolucci T. et al. (2020), encompassing a total of 1,370 patients with osteoarthritis affecting primarily the knees, ankles, hands, neck and lower back. Overall, these studies showed that electromagnetic therapy (mostly PEMF) reduced pain, improved physical function and reduced stiffness while being well tolerated. It could be a useful addition to the standard of care currently available to patients, although much remains to be done in optimizing protocols and validating them with larger trials.
 
Since then a number of new randomized controlled clinical studies were reported through 2025. We will summarize some of the more relevant ones below:
 
Hashemi, S. E. et al. (2024) conducted a small study with 70 female patients with primary knee OA. It investigated the effect of low-frequency PEMF (10-100 Hz; the device used was poorly identified but could be an Extremely Low Frequency (<100 Hz) and Low Intensity (< 10 mT) ASA Magnetotherapy device) in addition to a regular schedule of physical therapy. Exposure was 30 minutes at 40% intensity every week day for 3 weeks. Evaluations were conducted at baseline, after 3 weeks of treatment, and at 7 weeks follow-up. The results showed that the PEMF group experienced less pain (measured by the Visual Analog Scale, VAS), lower functional limitation, and reduced stiffness at 7 weeks compared to sham group. Physician Global Assessment (PGA) scores were also superior in the PEMF group versus sham.
 
Similarly to the previous study, Wang, Q. W. et al. (2024) investigated the effect of PEMF in a group of 60 patients with confirmed end-stage osteoarthritis (Kellgren-Lawrence (KL) grade ≥ 3) in one or both knees. PEMF treatment was administered in addition to home-based stretching and strengthening exercises designed by physiotherapists. PEMF treatment consisted of two 10-minute sessions per week for 8 weeks delivered by a Quantum Tx machine generating a uniform 1 mT field intensity at 50 Hz pulse frequency. Both knees were treated in alternate sessions, so each knee was exposed to a total of 8 sessions. Evaluations were conducted at baseline and at 4 and 8 weeks of treatment. The results showed improved knee muscle strength and reduced pain as well as a promising tendency to improve performance-based physical function (as measured by 6-meter walk plus sit-to-stand time) in the PEMF group versus sham.
 
Taken together, both studies supported supplementing exercise and physical therapy routines for knee OA patients with PEMF treatment. The magnetic pulse intensity and frequency required did not exceed 10 mT and 100 Hz, respectively. Session duration was 10 to 30 minutes at a frequency of 2 to 5 sessions per week for no more than 8 weeks. The duration of the beneficial effect beyond 8 weeks and the need for repetition remain to be determined. A recent review by Bhutada, G. et al. (2025) supports this conclusion.
 
Maghroori, R. et al. (2025) further investigated the utility of PEMF as adjunct therapy in a more complex setting where the patient population was already subjected to two forms of therapy: an exercise regimen plus a nonsteroidal anti-inflammatory drug, meloxicam 15 mg daily. PEMF treatment consisted of a 30-minute session with pulse intensity and frequency of 50 Gauss (5 mT) and 75 Hz, respectively. Each patient in a group of 60 diagnosed with grade 2 or 3 knee OA, was treated with 8 sessions of PEMF or sham PEMF over 3 weeks. Evaluations at baseline, end of treatment, and follow-up at 6 weeks and 3 months after treatment showed that the addition of PEMF therapy substantially enhanced pain relief and physical function with no reported side effects. The findings support the use of PEMF as adjunct therapy for knee OA patients who are concomitantly treated with exercise and an NSAID agent.
 
In a similar complex setting comprising a population of 120 patients suffering from knee OA, Kellgren-Lawrence (KL) grade ≥ 2, Wang, R. et al. (2026) investigated the effect of adding PEMF to two established therapies in China: exercise and external Chinese herbal therapy (Sanqi Shengyu External Application Cream). The PEMF protocol was distinct in using a much higher magnetic pulse intensity of 800 mT at a pulse frequency of 50 Hz for 30 minutes. Patients in the PEMF group were treated for a total of 20 sessions over 4 weeks. Evaluations were conducted at baseline, end of treatment, and at 4-week follow-up. The results of 4 treatment arms (exercise only as control, exercise + PEMF, exercise + external Chinese herbal therapy, and combination of exercise + PEMF + external Chinese herbal therapy) showed that the combined therapy group demonstrated superior outcomes, especially at the 4-week follow-up. The beneficial effect of external Chinese herbal therapy alone was durable, while that of PEMF diminished over time after intervention. The exercise-only control group also showed significant improvements but less pronounced than the active intervention groups.
 
Direct comparison of the results by Maghroori, R. et al. (2025) and Wang, R. et al. (2026) would not be possible because of the differences in PEMF protocols and control design. Nevertheless, both sets of results support the application of PEMF as an adjunct to multimodal therapies that include exercise and anti-inflammatory agents. Studies to optimize PEMF dosing (i.e. carrier frequency, pulse intensity and frequency, treatment duration required to achieve specific goals: pain & stiffness reduction, function improvement, cartilage degradation) are crucial for advancing PEMF as a treatment option. To that effect, Yang, X. et al. (2025) reported that at fixed magnetic field intensity (3.8 mT), higher PEMF pulse frequency (75>50>8 Hz) resulted in better recovery in a rat model of knee osteoarthritis. Ye, L. I. (2025)   reported some preliminary efforts in studies of varying field intensity in a mouse model, but detailed results have yet to be published.
 
Two additional clinical trial results need to be discussed as a separate category considering the characteristics of the PEMF protocols and the commercial nature of the devices employed. In contrast to PEMF protocols using magnetic pulse intensity in the mT range and pulse frequency < 100 Hz, the following two trials employed PEMF with carrier frequency in the radiofrequency (27.12 MHz) range, i.e. magnetic pulse intensity probably in the μT range or less, and pulse frequency ranging from 2 to 1,000 Hz. At such low intensity and wide range of pulse frequencies these electromagnetic pulses (often referred to as Pulsed Radiofrequency/Shortwave Therapy, or PRF/PSWT) can still penetrate soft tissue to disrupt chronic pain signaling and induce analgesia, among other effects. Whether the two distinct sets of protocols operate similarly at the cellular or molecular level remains to be determined for particular biological applications
 
Hackel, J. G. et al. (2025) reported a prospective study with 120 patients suffering from diverse soft tissue or joint pain (ankle, back, knee, wrist, elbow, shoulder, foot, hip, or neck) although knee pain predominated (43%) . Patients were randomized, but the study was not blinded and included two arms: PEMF and Standard of Care (SOC). Patients in the PEMF arm self-administered the treatment with a commercial device (Orthocor Active System) operating at 27.12 MHz carrier radiofrequency, pulse frequency of 2 Hz, pulse duration of 2 ms, and classified by the FDA as a short-wave diathermy device. The treatment consisted of daily 2-hour sessions for 14 days per manufacturer instructions. After 14 days, patients in the SOC arm were allowed to cross over. The two key endpoints for the study were efficacy measured by changes in pain score from baseline, and safety measured by the number of adverse events. The overall results showed that use of the Orthocor device was safe and led to significant reductions in pain and medication use compared to the standard of care for joint and soft tissue pain.
 
Durtschi, M. S. et al., 2025, reported on a single-center, double-blind, randomized, controlled trial with 61 patients suffering from thumb carpometacarpal (CMC) osteoarthritis to test the effectiveness of another commercial PEMF device, the ActiPatch made by BioElectronics, classified by the FDA as Non-Thermal Shortwave Device. The device operates at 27.12-MHz carrier radiofrequency, pulse frequency of 1,000 Hz, pulse duration of 0.1 ms. The study consisted of two arms: patients in a treatment group wore the device overnight for 4 weeks whereas patients in the control group similarly wore a sham device not emitting the radiowave. Two endpoints were considered: pain reduction and function improvement. Evaluations were conducted at baseline, at 4 weeks end of treatment, and at 6 weeks follow-up. The results showed that both PEMF and sham groups achieved pain reduction and function improvement at the end of treatment (4 weeks), but no statistical difference could be discerned between the two groups. At 6 weeks follow-up, however, the pain reduction was sustained in the PEMF group only. The placebo effect was substantial but did not extend beyond the treatment period. 

Effectiveness ranking of PEMF versus Extracorporeal shock wave therapy (ESWT), Low-level laser (LLLT) and Microwave (MW) therapy.

In a study of 120 patients aged 40-70 and diagnosed with knee OA, Kellgren-Lawrence (KL) grade 2-3, Pasin, T., & Dogruoz Karatekin, B. (2025) compared the efficacy of PEMF against two other non-pharmacological treatment modalities: extracorporeal shock wave therapy (ESWT) and low-level laser therapy (LLLT). The patients were divided into four groups of 30 participants each —three groups received their respective treatment interventions while one served as untreated control. The PEMF intervention consisted of 20-minute sessions twice weekly over 4 weeks, using a magnetic pulse intensity of 10 mT and and frequency of 30Hz. Overall, beneficial effects (pain reduction, decreased stiffness, and improved physical functions) were observed for all 3 interventions compared to the control group. However, PEMF was found to be less effective than ESWT and LLLT, which demonstrated roughly equal effectiveness. In summary: ESWT ≈ LLLT > PEMF.
 
In another comparative study, Comino-Suárez, N. et al. (2025) investigated the effects of PEMF and microwave therapy (MW) combined with a standardized exercise regimen (EX). This three-arm randomized, blinded clinical trial included 60 patients with unilateral or bilateral knee osteoarthritis, Kellgren & Lawrence grade 2 or 3, divided into groups receiving EX+PEMF, E+sham PEMF, and EX+MW. All three interventions were delivered over 12 sessions (3 sessions per week for 4 weeks). The PEMF treatment consisted of 20-minute exposures at a pulse intensity of 10 mT and frequency of 50 Hz. Results showed that although all three groups exhibited improvement in most VAS and WOMAC scores after treatment and at 1- and 3-month follow-ups, the EX+PEMF group outperformed the other two, particularly during the 1- and 3-month follow-up periods.
 
These finding complement and extend the report by Cao, S. et al. (2024) who compared the effectiveness of acupuncture for knee OA against 6 other non-pharmacological treatment modalities: needle-knife therapy (acupotomy), exercise, transcutaneous electrical nerve stimulation (TENS), ultrasound, shock wave therapy, and laser therapy (see our previous blog, 11/15/2025). Shock wave therapy was superior to all others based on VAS and WOMAC scale assessment following treatment.

Mechanistic aspects
 
Studies on the mechanism of pain modulation and articular cartilage stabilization by PEMF (Pilla, A. et al., 2011, Iwasaka, K. & Reddi, A., 2018, Bragin, D. E. et al., 2015) established the following basic understanding:

• PEMF modulates the calmodulin (CaM)-dependent nitric oxide (NO) signaling cascades in cells of inflamed joints, leading to an increase in the production of anti-inflammatory cytokines (e.g., IL-10, IL-13, sIL-1R) and a decrease in pro-inflammatory cytokines (e.g., IL-1 α/β, IL-6, TNF-α) by inhibiting the NF-κB pathway. The overall effect is a decrease in physiological pain mediators (bradykinin, prostaglandins, histamine) and enzymes responsible for degrading the cartilage matrix (MMPs and ADAMs).

 

• In addition, PEMF up-regulates the adenosine receptors A2A and A3 to stimulate chondrocyte proliferation, differentiation, and extracellular matrix synthesis through the release of anabolic morphogens, such as bone morphogenetic proteins and anti-iinflammatory cytokines.

 

• Acting through calmodulin (CaM)-dependent nitric oxide (NO) signaling cascades, PEMF also increases microvascular perfusion and oxygenation of tissues.

 
Since 2020, additional advances have been achieved in delineating the molecular features of osteoarthritic tissues and how they are affected by PEMF treatment . These advances are summarized below:
 
Using a cellular model of human chondrocytes (C28/I2) stimulated with interleukin (IL)-1β and a mouse model of osteoarthritis, Zhou, S. et al. (2025) demonstrated that upregulation of Sirt1 (a transcription factor deacetylase) by PEMF blocks the activation of the pivotal pro-iinflammatory NF-κB signaling pathway, which is often overactive in osteoarthritic joints. This finding is important as it adds to our understanding of the molecular events induced by PEMF that lead to decreased inflammation at the joints and slowing of disease progression. Inhibiting the NF-κB signaling pathway induced by interleukin (IL)-1β is part of an overall strategy for developing therapeutic agents for the treatment of osteoarthritis.
 
Working with primary human chondrocytes, Bao, C. et al. (2025) showed that the glycolysis rate increases in chondrocytes from arthritic cartilage, accompanied by upregulation of hexokinase II (HEK2). Overexpression of HEK2 promotes an inflammatory response and catabolism while inhibiting anabolic activities. Concommitant with the increased expression of HK2 was a decrease in expression of HMGA2, a DNA-binding protein capable of transcriptional regulation. The authors also showed that PEMF inhibits the expression of HEK2 and increases HMGA2, leading to a reversal of the iinflammatory and catabolic state in the chondrocytes. Lonidamine, an inhibitor of HK2, performed similarly. In a mouse model of osteoarthritis, lonidamine in combination with PEMF more effectively reversed cartilage degeneration. Finally, HK2 was proposed as a potential target for developing therapeutic agents for the treatment of osteoarthritis.
 
Over past decades, exposure to PEMF has been shown to have beneficial effects not only in bone and cartilage but also in tendons and muscles. Tendinopathy and muscle atrophy tend to stress joint structures and contribute to the development of osteoarthritis. As a result, mechanistic studies in those tissues were also of interest. The information developed from either approach tends to enhance and complement each other.
 
Using proteomic analysis of rat muscles subjected to experimentally induced tendinopathy, Torretta, E. et al. (2024) reported that glycolysis in these tissues is enhanced. When exposed to PEMF, changes in the pattern of cellular proteins support a switch towards oxidative phosphorylation, as evidenced by the increase in LDHB, which converts lactate to pyruvate, boosting NAD+ signaling, ATP production, and beta-oxidation of fatty acids. PEMF also increases the level of antioxidant proteins which control the damage caused by reactive oxygen species (ROS). Two key transcription co-activators, PGC1alpha and YAP, were upregulated by PMEF. The former is clearly linked to the increase in oxidative metabolism, anti-iinflammatory state, and antioxidant effects. The latter supports tissue repair and regeneration, and cell proliferation (Maiullari, S. et al., 2023). 

PEMF devices available to medical professionals and consumers
 
In a previous blog post (01/19/2025) we discussed various venues for accessing electromagnetic therapy for pain management. Now we’ll dwell into the devices available on the market for both medical professionals (doctors, therapists) and the general consumers responding to medical guidance, or just interested in self-help for osteoarthritis. The market can be broadly categorized into devices cleared by regulatory bodies for specific medical uses and those marketed for general health, pain, and wellness (more common in the consumer market).
 
I. Medical Device Market (Often FDA-Cleared/Approved)
 
These devices are typically intended for use under the guidance of a healthcare professional, with specific indications for use that may include post-operative pain, edema, and osteoarthritis.

​Note: While the primary FDA indications for many Orthofix and DJO devices are bone healing (non-union fractures or spinal fusion), PEMF technology, in general, is cleared for conditions like post-operative osteoarthritis and pain/edema. The ActiPatch is specifically cleared for knee osteoarthritis for non-prescription use. Except for the two Orthofix devices (Physio-Stim and Spinal-Stim) all others in the list are in fact Pulsed Radiofrequency/ Shortwave Therapy types operating at 27.12 MHz carrier frequency.
 
II. Health & Wellness Consumer Market
 
These are typically sold directly to consumers for home use, often marketed for general wellness, pain relief, improved circulation, and reduced inflammation, which are beneficial for osteoarthritis symptoms. They may not have specific FDA clearance for treating osteoarthritis but are marketed under general wellness claims.

​Concluding remarks
 
The available evidence supports the effectiveness of PEMF as an adjunctive treatment for different forms of osteoarthritis, particularly for relief from pain and inflammation. Proof of a beneficial effect on cartilage degradation remains at the experimental level in animal models. It has yet to be validated quantitatively in a randomized clinical setting with adequate control. Conservatively, patients could opt for any of the FDA-approved device and protocol under guidance from medical professionals, and as adjunct to exercises and physical therapy in addition to judicious application of pharmacological interventions. Devices approved for marketing for home use and general wellness are likely safe enough for those willing to explore therapeutic approaches still under development.

References
 
Wu, Ziying, Xiang Ding, Guanghua Lei, Chao Zeng, Jie Wei, Jiatian Li, Hui Li et al. "Efficacy and safety of the pulsed electromagnetic field in osteoarthritis: a meta-analysis." BMJ open 8, no. 12 (2018): e022879. doi: 10.1136/bmjopen-2018-022879 https://doi.org/10.1136/bmjopen-2018-022879
 
Paolucci, T., Pezzi, L., Centra, A. M., Giannandrea, N., Bellomo, R. G., & Saggini, R. (2020). Electromagnetic field therapy: a rehabilitative perspective in the management of musculoskeletal pain–a systematic review. Journal of pain research, 1385-1400. DOI https://doi.org/10.2147/JPR.S231778 https://doi.org/10.2147/JPR.S231778
 
Hashemi, S. E., Gök, H., Güneş, S., Ateş, C., & Kutlay, Ş. (2024). Efficacy of pulsed electromagnetic field therapy in the treatment of knee osteoarthritis: A double-blind, randomized-controlled trial. Turkish Journal of Physical Medicine and Rehabilitation, 71(1), 66. doi: 10.5606/tftrd.2024.14486
 
Wang, Q. W., Ong, M. T. Y., Man, G. C. W., Franco-Obregón, A., Choi, B. C. Y., Lui, P. P. Y., ... & Yung, P. S. H. (2024). The effects of pulsed electromagnetic field therapy on muscle strength and pain in patients with end-stage knee osteoarthritis: A randomized controlled trial. Frontiers in Medicine, 11, 1435277. https://doi.org/10.3389/fmed.2024.1435277
 
Bhutada, G., Telang, A. A., & Yadav, V. (2025). Impact of Pulsed Electromagnetic Field Therapy Combined With Traditional Exercises on Knee Osteoarthritis Pain, Range of Motion, and Functional Activities-A Review Article. Research Journal of Science and Technology, 17(3), 220-224. https://rjstonline.com/HTML_Papers/Research%20Journal%20of%20Science%20and%20Technology__PID__2025-17-3-4.html
 
 
Maghroori, R., Safinataj, S., & Vahdatpour, B. (2025). Efficacy of Pulsed Electromagnetic Field Therapy as an Adjunct to Meloxicam and Exercise in Grade II and III Knee Osteoarthritis: A Randomized, Single-Blind Clinical Trial. Middle East Journal of Rehabilitation and Health Studies, 13(13), e164013. https://doi.org/10.5812/mejrh-164013
 
Wang, R., Li, F., Xia, M., Bu, Q., Li, L., Li, X., ... & Yang, L. (2026). Effects of Sanqi Shengyu External Application Cream and Pulsed Electromagnetic Field on Knee Osteoarthritis in Older Adults: A Randomized Controlled Trial. Physiotherapy Research International, 31(1), e70121.  
https://doi.org/10.1002/pri.70121
 
Yang, X., Li, X., Song, H., Wu, T., Li, J., & He, C. (2025). Effects of Whole‐Body Exposure to Pulsed Electromagnetic Field at Different Frequencies on Knee Osteoarthritis. Bioelectromagnetics, 46(6), e70016. https://doi.org/10.1002/bem.70016
 
Ye, L. I. (2025). The Mechanism of Pulsed Electromagnetic Field (PEMF) Therapy for Cartilage Degradation-Driven Knee Osteoarthritis (KOA): Do Magnetosensitive Protein Complexes Exist?. Osteoarthritis and Cartilage, 33(6), 821. DOI: 10.1016/j.joca.2025.03.088 
 
Hackel, J. G., Paci, J. M., Gupta, S., Maravelas, D. A., North, T. J., & Paunescu, A. (2025). Evaluating Noninvasive Pulsed Electromagnetic Field Therapy for Joint and Soft Tissue Pain Management: A Prospective, Multi-center, Randomized Clinical Trial. Pain and Therapy, 14(2), 723-735. https://doi.org/10.1007/s40122-025-00711-z
 
Durtschi, M. S., Rajakumar, V., Kenney, D. E., Pham, N. S., Ladd, A. L., & Chou, R. C. (2025). Clinical Efficacy of Pulsed Electromagnetic Field Therapy on Thumb Carpometacarpal Joint Pain: A Double-Blind, Randomized, Controlled Trial. HAND, 15589447251371088. https://doi.org/10.1177/15589447251371088
 
Pasin, T., & Dogruoz Karatekin, B. (2025). Comparison of Short-Term effects of extracorporeal shock wave therapy, Low-Level laser therapy and pulsed electromagnetic field therapy in knee osteoarthritis: A randomized controlled study. Journal of Clinical Medicine, 14(2), 594. https://doi.org/10.3390/jcm14020594
 
Comino-Suárez, N., Jiménez-Tamurejo, P., Gutiérrez-Herrera, M. A., Aceituno-Gómez, J., Serrano-Muñoz, D., & Avendaño-Coy, J. (2025). Effect of pulsed electromagnetic field and microwave therapy on pain and physical function in older adults with knee osteoarthritis: A randomized clinical trial. Journal of Geriatric Physical Therapy, 10-1519. DOI: 10.1519/JPT.0000000000000444
 
Cao, S., Zan, Q., Wang, B., Fan, X., Chen, Z., & Yan, F. (2024). Efficacy of non-pharmacological treatments for knee osteoarthritis: A systematic review and network meta-analysis. Heliyon, 10(17). DOI: 10.1016/j.heliyon.2024.e36682
 
Pilla, A., Fitzsimmons, R., Muehsam, D., Wu, J., Rohde, C., & Casper, D. (2011). Electromagnetic fields as first messenger in biological signaling: application to calmodulin-dependent signaling in tissue repair. Biochimica et Biophysica Acta (BBA)-General Subjects, 1810(12), 1236-1245. https://doi.org/10.1016/j.bbagen.2011.10.001
 
Iwasa, K., & Reddi, A. H. (2018). Pulsed electromagnetic fields and tissue engineering of the joints. Tissue Engineering Part B: Reviews, 24(2), 144-154. https://doi.org/10.1089/ten.teb.2017.0294
 
Bragin, D. E., Statom, G. L., Hagberg, S., & Nemoto, E. M. (2015). Increases in microvascular perfusion and tissue oxygenation via pulsed electromagnetic fields in the healthy rat brain. Journal of neurosurgery, 122(5), 1239-1247. DOI link: 
https://doi.org/10.3171/2014.8.JNS132083
 
Zhou, S., Wen, H., He, X., Han, X., & Li, H. (2025). Pulsed electromagnetic field ameliorates the progression of osteoarthritis via the Sirt1/NF-κB pathway. Arthritis research & therapy, 27(1), 33. https://doi.org/10.1186/s13075-025-03492-0
 
Bao, C., Zhu, S., Pang, D., Yang, M., Huang, J., Wang, F., ... & He, C. (2025). Hexokinase 2 Suppression Alleviates the Catabolic Properties in Osteoarthritis via HMGA2 and Contributes to Pulsed Electromagnetic Field-mediated Cartilage Protection. International Journal of Biological Sciences, 21(4), 1459. https://doi.org/10.7150/ijbs.101597
 
Torretta, E., Moriggi, M., Capitanio, D., Orfei, C. P., Raffo, V., Setti, S., ... & Gelfi, C. (2024). Effects of pulsed electromagnetic field treatment on skeletal muscle tissue recovery in a rat model of collagenase-induced tendinopathy: results from a proteome analysis. International Journal of Molecular Sciences, 25(16), 8852.  https://doi.org/10.3390/ijms25168852
 
Maiullari, S., Cicirelli, A., Picerno, A., Giannuzzi, F., Gesualdo, L., Notarnicola, A., ... & Moretti, B. (2023). Pulsed electromagnetic fields induce skeletal muscle cell repair by sustaining the expression of proteins involved in the response to cellular damage and oxidative stress. International Journal of Molecular Sciences, 24(23), 16631.  https://doi.org/10.3390/ijms242316631

​Introduction
 
In a previous blog, we discussed two non-pharmacological treatment options for osteoarthritis: exercise and low-dose radiation therapy. Today, we turn to the realm of alternative medicine and examine the role of acupuncture. Practitioners of Traditional East Asian Medicine (TEMA) would likely laugh and brush off the question of whether acupuncture works for osteoarthritis. Specific acupuncture points for treating knee, hip, and shoulder pain were described in classical texts centuries ago—although, of course, not in modern Western medical terms. TEMA practitioners do not question acupuncture’s efficacy; they rely on the accumulated experience of generations before them.
 
In the Western medical tradition, however, anecdotal experience alone is not accepted as proof of effectiveness. We expect evidence from rigorous clinical trials, ideally double-blinded and randomized. In this review, we will focus on the clinical evidence available to date regarding acupuncture’s efficacy in knee osteoarthritis, along with research into its potential mechanisms for pain reduction and functional improvement. We will also situate acupuncture within the context of current standards of care for knee osteoarthritis and compare these findings with recommendations from professional medical societies and governmental health agencies.
 
We will not address how to locate the “best” acupuncture practitioners for osteoarthritis, as recommendations from physicians, relatives, and friends are often the most reliable—though, of course, you may also consult your favorite AI chatbot.

The Effect of Acupuncture on Knee Osteoarthritis Pain
 
As discussed in the 02/24/2024 blog post, President Richard Nixon’s 1972 visit to China and the cultural exchanges that followed greatly increased Western interest in acupuncture. Scientific research and clinical trials expanded rapidly. To date, these trials support acupuncture as an effective, safe, and recommended therapy for the symptomatic management of pain, including osteoarthritis pain. However, most studies have been relatively small and heterogeneous in terms of patient selection, acupuncture techniques, treatment duration, and control group design (single-blind, double-blind, placebo, no treatment, etc.). High-quality randomized controlled trials and meta-analyses provide the most meaningful insights, summarized below. Comparisons between acupuncture and various control conditions (1) were as follows:
 

• Acupuncture versus sham acupuncture: Pooled results indicate that acupuncture may improve both overall pain and function for up to 4.5 months after treatment.
• Acupuncture versus usual care: Pain relief and improved function may last up to 5 months. “Usual care” typically includes some combination of patient education, weight management, exercise, orthotic devices, oral or topical analgesics, and physical therapy.

 

• Acupuncture versus diclofenac: Studies report pain relief and functional improvement lasting up to 6 months after treatment.

 

• Acupuncture versus no treatment: Results were less consistent. One study found significant pain reduction and functional improvement for up to 3 months, while another reported only modest pain reduction at the end of treatment and none at 9-month follow-up.

 

• Acupuncture + exercise-based physical therapy versus sham acupuncture + exercise-based physical therapy: No additional benefit from acupuncture was observed for up to 11.25 months.

 

• Acupuncture + exercise-based physical therapy versus exercise-based physical therapy alone: A significant reduction in overall pain was noted 0.75 months (approximately 3 weeks) after treatment.

 
Overall, current clinical evidence indicates that acupuncture can reduce pain and improve function in knee osteoarthritis patients for 3 to 6 months after treatment. Reported adverse events were mild and transient—mainly brief needling pain and small hematomas. Only a small percentage of participants experienced side effects, reinforcing that acupuncture is a generally safe treatment option. The studies included all three commonly used forms of acupuncture: manual, electroacupuncture, and dry needling. Acupuncture points used across studies were standard points traditionally selected for knee osteoarthritis.

Acupressure effectiveness
 
Acupressure is a less invasive variant of acupuncture in which pressure is applied to the same acupoints used in traditional needling. Recently, Yeung, W.-F. et al. (2) reported the results of a randomized, controlled clinical trial involving 314 middle-aged and older adults with probable knee osteoarthritis. Participants in the treatment group were trained to perform self-administered acupressure, while the control group received only knee health education.
 
The study found that acupressure produced meaningful pain reduction lasting up to 3 months. However, improvements in physical function did not reach statistical significance. Only 13% of participants reported mild, self-resolving adverse events.
 
Overall, acupressure appears to be a safe and effective method for managing knee osteoarthritis pain, and it is also highly cost-effective due to its self-care nature. Following are three Youtube videos for self-help.

Comparison with other non-pharmacological therapies
 
A natural next question is how acupuncture compares with other non-pharmacological therapies for knee osteoarthritis. Numerous clinical studies have evaluated one non-pharmacological treatment against another. More recently, Cao, S. et al. (3) conducted a network meta-analysis comparing the clinical efficacy of seven distinct non-pharmacological therapies for knee osteoarthritis, including acupuncture. The other therapies evaluated were needle-knife therapy (acupotomy), exercise, transcutaneous electrical nerve stimulation (TENS), ultrasound, shock wave therapy, and laser therapy.
Pain and symptom assessments were based on two standard tools: the Visual Analog Scale (VAS) and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC).
 

• VAS is a simple 100-mm line used to measure pain intensity, anchored by “no pain” (0) and “worst possible pain” (100).

 

• WOMAC is a patient-reported questionnaire assessing pain, stiffness, and physical function. Scores range from 0 to 4, with higher scores indicating more severe symptoms.

 
The results of the network meta-analysis were as follows:
 
Efficacy rankings based on VAS pain scores:
shock wave therapy > needle-knife > laser therapy > acupuncture > ultrasound > exercise > transcutaneous electrical nerve stimulation
 
Efficacy rankings based on total WOMAC score:
shock wave therapy > needle-knife > laser therapy > acupuncture > ultrasound > transcutaneous electrical nerve stimulation > exercise
 
Efficacy rankings based on WOMAC subscales:
 

• Pain: shock wave therapy > needle-knife > laser therapy > acupuncture > exercise > transcutaneous electrical nerve stimulation > ultrasound

 

• Stiffness: laser therapy > exercise > shock wave therapy > acupuncture > needle-knife > ultrasound > transcutaneous electrical nerve stimulation

 

• Physical function: shock wave therapy > laser therapy > needle-knife > acupuncture > ultrasound > transcutaneous electrical nerve stimulation > exercise

 
In nearly all ranking systems—except for the WOMAC stiffness subscale—shock wave therapy emerged as the most effective treatment. Acupuncture consistently ranked in the middle tier. TENS, exercise, and ultrasound generally ranked the lowest, depending on the specific measure.
 
What these rankings mean for patient care and clinical practice remains uncertain. Importantly, the authors of the study explicitly caution that additional rigorous, well-designed randomized controlled trials are still needed to validate and refine these conclusions.

Mechanistic aspects
 
Multiple animal and human studies have shown that acupuncture exerts anti-inflammatory effects in the synovium, influences cartilage homeostasis, and modulates neural pathways involved in pain perception (4–6).
 

• Anti-inflammatory effects: Acupuncture and electroacupuncture have been shown to reduce pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) while increasing anti-inflammatory cytokines such as IL-10. These shifts are believed to contribute to pain reduction and slower cartilage degradation.

 

• Effects on cartilage metabolism: Animal and in vitro studies have demonstrated acupuncture-associated changes in the expression of matrix metalloproteinases (MMPs) and their inhibitors, suggesting a decrease in proteoglycan and collagen breakdown. However, translating these findings from animal histology to human clinical outcomes remains limited.

 

• Cartilage regeneration: Evidence that acupuncture can regenerate human cartilage—such as increasing cartilage thickness or restoring hyaline cartilage—is currently insufficient. Most supportive data come from preclinical studies in animal models or small human biomarker studies. Large clinical trials with MRI-based structural endpoints are lacking. Therefore, the most defensible current claim is chondroprotection and anti-catabolic modulation, rather than proven cartilage regeneration in humans.

 

• Analgesic mechanisms: Acupuncture stimulates somatic sensory afferent nerves and activates central descending pain-inhibitory pathways, including endogenous opioid, serotonergic, and noradrenergic systems.

 

• Molecular signaling pathways: Acupuncture exerts its effects by modulating several key molecular pathways, including norepinephrine (NE) signaling, the TLR/NF-κB pathway, the MCP-1/CCR2 axis, the NLRP3 inflammasome, and the Ras–Raf–MEK1/2–ERK1/2 cascade. Advances in understanding these pathways may help identify molecular targets for future drug development.

 
Much progress has been made in elucidating the mechanisms underlying acupuncture’s clinical benefits. Future human studies, particularly those focusing on optimal dosing and the key pathways involved in synovial stabilization, will improve our understanding of knee osteoarthritis and help solidify acupuncture’s role as an evidence-based treatment option.

Guidelines by professional societies and government health agencies
 
The American College of Rheumatology (ACR) and Arthritis Foundation, the American Academy of Orthopaedic Surgeons (AAOS), and the Osteoarthritis Research Society International (OARSI) all limit their recommendations for acupuncture to conditional, limited, or uncertain (7–9). The National Center for Complementary and Integrative Health (NCCIH) aligns its guidance with the ACR/Arthritis Foundation recommendations. Core non-pharmacological treatments for knee osteoarthritis continue to emphasize self-management programs, aerobic and/or strength-training exercise, and weight loss for individuals who are overweight. Notably, Tai Chi is strongly recommended as a form of therapeutic exercise.
 
The National Institute for Health and Care Excellence (NICE) in the UK stands out with its more definitive position, issuing a “not recommended” guideline for acupuncture in knee osteoarthritis (10). However, NICE acknowledges in its commentary that electroacupuncture may have potential benefits, while also noting that the specific patient population likely to respond is unclear. NICE additionally concluded that acupuncture is not cost-effective based on its economic assessments.
 
It is important to recognize that these guidelines may not reflect the most recent evidence. The ACR/Arthritis Foundation, AAOS, and OARSI recommendations were published in 2019, 2021 and 2019, respectively, while NICE’s guidance dates to 2022. The cautious and conservative positions of these organizations are understandable given the shortcomings of the acupuncture trials and the lack of large, industry-funded studies of the type commonly performed for pharmaceuticals.

Implications for the patients
 
Navigating the increasing amount of information on acupuncture for osteoarthritis depends greatly on the preferences and inclinations of both patients and their physicians. Incorporating this information into patient education programs can certainly help patients make more informed decisions.
 
From this author’s perspective, acupuncture is a reasonable and viable option when core recommendations and standard drug therapies fail to meet a patient’s needs. It is also an option worth considering before turning to more aggressive interventions such as radiation therapy or surgery.

Introduction
 
Osteoarthritis (OA) is a chronic, degenerative disease of synovial joints, characterized by progressive articular cartilage degradation, subchondral bone remodeling, osteophyte formation, synovial inflammation, changes in periarticular muscles, and alterations in joint biomechanics. Clinically, patients typically present with joint pain (often worse with weight-bearing or movement), stiffness after inactivity, reduced range of motion, crepitus, swelling, and functional limitation. Symptoms tend to develop insidiously and may worsen over time, occasionally punctuated by acute exacerbations.

Epidemiology
 
OA is among the leading causes of disability globally. According to recent estimates, there are more than 600 million people living with OA worldwide, with age-standardized prevalence steadily increasing over recent decades (Zhang, X. et al., 2025, Wang, Z. et al., 2024). Knee OA is especially common; its global lifetime risk is approximately 9.3%. Hip OA, hand OA, and other joint-specific OA forms also contribute to the total burden (Litwic et al, 2013, WHO, 2023). Regionally, prevalence is higher in high-sociodemographic index (SDI) and high-income regions, including much of Europe. For instance, a systematic review of hip OA found a radiographic prevalence of around 12.6% in Europe (versus lower estimates in other regions). Across Europe, prevalence varies by region (Eastern, Central, Western), with    around 7–8% (for total OA) and higher incidence and disability in Western Europe. The disease accounts for large numbers of years lived with disability (YLDs) and its burden is increasing, driven by population aging, obesity trends, and increased survival from other diseases.

Risk Factors
 
Osteoarthritis is etiologically heterogeneous. Key non-modifiable risk factors (Allen, K.D. et al., 2022) include:

• Age: incidence and prevalence rise sharply with advancing age.
• Sex: women are at higher risk than men, particularly for knee and hand OA, especially post-menopause. (WHO, 2023)
• Genetic predisposition: multiple genetic loci and familial aggregation have been identified.

 
Important modifiable risk factors (Bortoluzzi,A. et al., 2018) include:

• Obesity / high body mass index (BMI): increases joint loading and may contribute via systemic inflammation.
• Prior joint injury or repetitive joint overuse (work- or sports-related trauma).
• Biomechanical factors: malalignment (varus/valgus in knees), joint shape abnormalities, muscle weakness and poor joint support.
• Metabolic factors: comorbidities including metabolic syndrome, diabetes, dyslipidemia. Emerging data suggest systemic contributors beyond purely mechanical stress.

 
Additional risk modifiers include lower socioeconomic status, some dietary factors, possibly vitamin insufficiencies, and lifestyle (physical inactivity). However, evidence is variable for these.

Clinical Presentation and Natural History
 
The onset of OA is gradual. Early disease may show radiographic changes without symptoms; conversely, symptomatic disease may precede severe structural damage. Pain, stiffness (especially mornings or after rest), crepitus, and limited joint mobility are typical. Over time, progressive joint destruction may lead to deformity, loss of function, disability, reduced quality of life, and often comorbidities due to sedentary behavior (cardiovascular disease, obesity, mood disorders).

Current Treatment Modalities
 
Standard management of osteoarthritis is multimodal and often tiered, combining non-pharmacologic with pharmacologic approaches, and in advanced disease, surgical interventions. The main modalities include:
 

1. Patient education and lifestyle modification: weight loss, diet, physical activity.
2. Exercise therapy: strength training, aerobic conditioning, flexibility, neuromuscular, and balance training.
3. Physical modalities: bracing, orthotics, assistive devices, manual therapy.
4. Pharmacologic treatments: analgesics (acetaminophen), nonsteroidal anti-inflammatory drugs (NSAIDs), topical agents; intra-articular injections (corticosteroids, hyaluronic acid) in selected cases.
5. Surgical options: osteotomy, joint replacement (e.g. total knee or hip arthroplasty) when conservative measures fail and quality of life is severely impaired.

 
While these approaches can ameliorate symptoms and improve function, pharmacologic and surgical interventions carry risks and costs. NSAIDs are associated with gastrointestinal, cardiovascular, and renal adverse effects; joint replacement surgery has operative risks, recovery burdens, and limitations in access. Because of these issues, there is increasing interest in safer, non-pharmacologic strategies that can be deployed earlier in the disease course.
 
In the following discussion, I will focus on two under-utilized but promising non-pharmacologic interventions for osteoarthritis: structured exercise programs (of various types) and low-dose radiation therapy. I will examine the evidence base for efficacy, mechanisms of action, dosing and safety, and discuss why low-dose radiation therapy is more commonly employed in European practice than in the United States. The goal is to assess how these modalities might complement or offer alternatives to pharmacologic treatments, especially for patients seeking long-term, low-risk, sustainable relief and functional improvement.

​The best current science and major clinical guidelines treat regular, structured exercise as the core (first-line) therapy for osteoarthritis and age-related joint pain, while recommending caution about routine, long-term use of systemic analgesics (especially oral NSAIDs) in older adults because of real safety risks. The guidelines, evidence, mechanisms, and practical implications are summarized below:

Major guidelines
 

• International and national guidelines put therapeutic exercise (individualized, structured, often strength + aerobic + neuromuscular work) at the center of non-surgical management for knee/hip OA and many older adults with joint pain. Examples: NICE (UK), OARSI, and the American College of Rheumatology (NICE Guidelines , 2022, Bannuru, R.R. et al., 2019, Kolasinski, S.L. et al., 2020).
• Geriatric prescribing guidance (AGS/Beers) flags regular, scheduled oral NSAID use as potentially inappropriate in many older adults because of dose-related gastrointestinal, renal and cardiovascular harms; it advises avoiding chronic use unless benefits clearly outweigh risks and monitoring closely if used (2023 American Geriatrics Society Beers Criteria® Update Expert Panel).

Evidence from systematic reviews and trials
 

• Exercise reduces pain and improves function. Large systematic reviews, Cochrane updates, and an individual-participant-data meta-analysis/IPD-meta (Holden et al. 2023) show that therapeutic exercise produces small but statistically significant improvements in pain and physical function versus non-exercise controls (short-term benefits are clearest). The IPD meta-analysis quantified short-term pain improvement at about −6.4 points on a 0–100 scale (95% CI −8.45 to −4.27); benefits persist but become smaller over medium/long term. People with higher baseline pain/function impairment tend to gain more (Lawford B.J. et al., 2024).
• Type of exercise. Multiple trials/meta-analyses find benefit from land-based therapeutic exercise overall; resistance (strength) training, neuromuscular/proprioceptive training, and aerobic activity all show benefit. No single exercise type is universally “best” — prescription should be tailored (strength + functional training is commonly recommended) (Young, J.J. et al., 2023, Lim, J. et al., 2024).
• Comparative landscape. Network meta-analyses that compare many treatments (pharmacologic and non-pharmacologic) find that many interventions can reduce OA pain, but heterogeneity and risk-of-bias make direct ranking difficult; nevertheless, exercise stands out as a low-risk, broadly beneficial option (Smedslund, G. et al., 2022).

Mechanism of action
 

• Muscle support & biomechanics: Strengthening peri-articular muscles reduces joint loading and improves joint control.
• Central and peripheral pain modulation (exercise-induced hypoalgesia): a single bout and regular training change pain processing (reduced pain sensitivity).
• Anti-inflammatory and metabolic effects: regular exercise lowers some pro-inflammatory cytokines (and reduces adiposity), which helps chronic, low-grade inflammation that contributes to OA pain. Reviews summarize these central and peripheral mechanisms (Hall, M. et al., 2020, Vaegter, H. B. & Jones, M. D, 2020, Kong H. et al., 2022).

Efficacy vs safety
 

• Oral NSAIDs (ibuprofen, naproxen, diclofenac, COX-2 inhibitors): effective analgesics for OA pain in many trials, but they carry real risks in older adults — dose-related increased risk of gastrointestinal bleeding, acute kidney injury/decline in renal function, and increased risk of acute myocardial infarction or other cardiovascular events in some settings. Because older adults often have comorbidities and take other drugs (anticoagulants, ACE inhibitors, diuretics), the absolute harms rise (Bally M. et al., 2017, Modig, S.& Elmståhl, S., 2018, 2023 American Geriatrics Society Beers Criteria® Update Expert Panel ).
• Topical NSAIDs: meta-analyses and reviews show topical NSAID preparations produce meaningful local pain relief with lower systemic adverse events than oral NSAIDs — often a reasonable first pharmacologic option for localized knee or hand OA pain (Rannou, F. et al., 2016, Wang, Y. et al., 2022).
• Paracetamol (acetaminophen): high-quality systematic reviews find minimal to no clinically important benefit of regular paracetamol for hip/knee OA pain. Long-term/parenteral use is not risk-free (liver injury, and other potential harms). Many guidelines now place paracetamol low in the treatment algorithm (or recommend it only for short-term “rescue” use) (Leopoldino, A.O. et al, 2019, McCrae, J. C. et al., 2018).
• Net clinical view (evidence + safety): pharmacologic agents can help short-term pain control, but the risk:benefit in older adults must be evaluated individually. This is precisely why guidelines emphasise exercise (benefit + exceptionally low systemic risk) as the foundation of care, and recommend cautious, often short-term or topical use of analgesics when needed (NICE Guidelines, 2022, Bannuru, R.R. et al., 2019).

Practical applications
 
Practical, evidence-based steps clinicians/guidelines recommend that reflect the science above:

1. Make exercise the core therapy. Start a tailored program combining local muscle strengthening (eg. quadriceps for knee OA), aerobic conditioning (walking, cycling, swimming), and balance/functional training. Supervision (physiotherapist or guided classes) improves adherence and outcomes (NICE Guidelines, 2022, Lawford B.J. et al., 2024).
2. Address weight if overweight. Combined exercise + weight loss improves pain more than either alone in overweight patients (NICE Guidelines, 2022).
3. Reserve oral NSAIDs for short, targeted use under medical supervision (lowest effective dose, shortest duration; consider GI protection and monitor renal function and BP). Avoid routine long-term scheduled oral NSAIDs in many older adults unless clinician judges benefits outweigh the risks (2023 American Geriatrics Society Beers Criteria® Update Expert Panel).
4. Prefer topical NSAIDs for localized OA pain when medication is needed — similar pain relief with lower systemic exposure (Rannou, F. et al., 2016, Wang, Y. et al., 2022).
5. Use paracetamol only as short-term rescue (not as the main long-term strategy) given small benefit and potential harm with long-term use. (Leopoldino, A.O. et al, 2019, McCrae, J. C. et al., 2018)

 
In summary, exercise is evidence-based first-line therapy for osteoarthritis and age-related joint pain: it reduces pain and improves function, carries low systemic risk, and has broader health benefits (cardiovascular, balance, fall prevention). Systemic analgesics (oral NSAIDs, long-term paracetamol) can help short-term but carry non-trivial harms in older adults and therefore should not be the primary long-term strategy without careful clinician oversight; topical options and time-limited oral use (lowest effective dose, monitoring) are safer choices when medication is necessary.

4–6-week evidence-based starter plan
 
The plan was designed for older adults with joint pain due to osteoarthritis or overuse and grounded in the research and recommendations discussed above. The focus is on:

• reducing pain and stiffness,
• improving strength, balance, and joint control,
• avoiding overuse or further inflammation.

 


General Principles Before Starting
 

1. Medical check: Confirm with your clinician that moderate activity is safe for you (especially if you have cardiovascular, balance, or orthopedic issues).
2. Pain rule: Some mild discomfort (≤3/10) during exercise is acceptable, but pain should not worsen or linger >24 hours after.
3. Frequency target: 5–6 days per week of some activity (mixing strength, mobility, and aerobic).
4. Warm-up and cool-down: 5 minutes of gentle motion before/after every session (slow marching, arm swings, ankle circles).
5. Equipment needed: Resistance bands, a sturdy chair, light weights (or water bottles), and comfortable shoes.

 
Please note if your attending physician prescribed specific exercises to be done under the supervision of a physical therapist. You should consult and coordinate with the physical therapist for any additional personal exercise program.

Key Modifications & Tips
 

• Pain flare: Replace high-load moves with isometric holds (e.g., wall sits, straight-leg raise).
• Swelling/inflammation day: Use gentle range-of-motion exercises or pool walking instead of strength work.
• Progression: Increase repetitions by 2–4 every 2 weeks or add light resistance band tension.
• Joint load reduction: Water-based exercise or recumbent cycling reduce compressive forces on knees and hips.
• Balance benefit: Add Tai Chi or yoga once weekly — supported by trials showing improvement in OA pain and proprioception.

Mechanistic Summary

• Strengthening muscles (quadriceps, glutes, core) reduces stress on joints by redistributing mechanical loads.
• Aerobic exercise improves circulation, reduces systemic inflammation (IL-6, TNF-α), and promotes synovial fluid turnover.
• Mobility and balance training maintain joint range and reduce the risk of falls and maladaptive compensatory gait.

​Recommended Videos & Highlights
 
YouTube videos on exercises for osteoarthritis abound. Here are my favorites addressing common osteoarthritis of the knee, hip and shoulders. Many of the exercises in the 4-6 Week Starter Plan will be demonstrated in the videos discussed below.

​Tips for Using These Videos Effectively & Safely
 

1. Start slowly & short. Even if the video is 20–30 minutes, you can pick 2–3 exercises initially until your tolerance in the affected joint builds.
2. Use support. Use a chair, wall, or stable object during standing moves to guard against slips or imbalance.
3. Consistency over intensity. Better to do 10 min daily than 30 min once and cause soreness.
4. Monitor response. If pain worsens (especially sharp pain, swelling, “giving way”), scale back immediately or skip that movement.
5. Mirror your own program. Use the videos to guide your form and variety, but keep your tailored 4–6-week program in mind.
6. Record or note the time stamps. If a particular exercise is especially good (e.g. mini-squats, heel raises, side leg lifts), note where in the video it is so you can return to it easily.

​LDRT as a treatment for osteoarthritis fell into disfavor in the United States decades ago (since the 80’s) due to concerns about secondary malignancies, advances in pharmacological treatment, and negative results from two significant randomized controlled trials (as cited below). Nevertheless, emerging data from the most recent meeting of the Association for Radiation Oncology (ASTRO) have rekindled interest. Reviewing the subject is certainly timely  for the benefit of the osteoarthritis community.

Nature of the Radiation Used
 
To be clear, low-dose radiation therapy (LDRT) for osteoarthritis (OA) is ionizing X-radiation, not radiofrequency or laser energy.

• X-rays (photon radiation) are used — the same physical type as diagnostic X-rays but with much lower energies than modern external beam (megavoltage) therapy used for cancer.
• Typical LDRT for benign and degenerative conditions employs orthovoltage (medium-energy) X-rays or low-megavoltage photon beams from linear accelerators (linacs).

 
The energy, wavelength, and frequency ranges employed are summarized in the table below.

​Purpose-built instruments are used for delivering the orthovoltage X-ray whereas low-megavoltage photons beams are derived from repurposed linear accelerators with calibrated dose planning system.

Mechanism of action
 
Low-dose radiotherapy (LDRT) is hypothesized to reduce pain in osteoarthritis (OA) by producing anti-inflammatory and immunomodulatory effects at doses well below those used in oncologic practice. Proposed mechanisms include altered polarization and reduced activity of inflammatory macrophages, decreased secretion of pro-inflammatory cytokines, modulation of endothelial adhesion molecules, and effects on nociceptive signaling within periarticular tissues. These biological effects have been demonstrated in preclinical models and are used to explain the rapid (weeks) to delayed (months) symptomatic improvements reported in clinical series (Weissmann, T. et al. ,2023, Dove, A. P. H. et al., 2022).

Typical dose and fractionation used in Europe
 
Patterns of care in Europe are relatively consistent: common regimens deliver 0.5–1.0 Gy per fraction with total doses in the ~3–6 Gy range, typically given as 2 fractions per week over 2–3 weeks (for example, 6 × 0.5 Gy = 3 Gy total; or 6 × 1 Gy = 6 Gy total). Some centers report variation (very low single-fraction schemes and higher cumulative doses in specific indications), but the 0.5 Gy/fraction × 6 fractions schedule is among the most frequently cited. National practice patterns (especially in Germany) historically have used these low-fractionation regimens for benign skeletal disorders (Dove, A. P. H. et al., 2022, Micke, O. et al., 2017).

​Summary of evidence from randomized trials, observational series, and recent data

• High-quality sham-controlled RCTs (negative): Two well-conducted, double-blind, sham-controlled randomized trials from the Netherlands found no clinically meaningful benefit of LDRT over sham in symptomatic hand OA (6 × 1 Gy vs sham) and in knee OA. Long-term follow-up of these parallel trials showed no delayed effect. These RCTs tempered enthusiasm generated by earlier observational reports. (Minten, M. J. M. et al., 2018, Mahler, E. A. M. et al., 2019).
• Large observational and registry series (positive): Numerous European retrospective and prospective series, and national patterns-of-care studies (particularly from Germany), report substantial pain relief and functional improvement in most treated patients; these studies also often report favorable safety profiles in older adults. Such series underpin routine LDRT use for benign musculoskeletal pain in parts of Europe. However, observational designs are susceptible to placebo effects, regression to the mean, and selection bias. (Keller, S. et al., 2013, Wiśniowska, A. et al., 2025).
• Recent/nascent randomized data (mixed/emerging): In 2025 several groups presented randomized data at international meetings (and professional society press releases) reporting benefit from modern LDRT regimens (for example, 3 Gy total delivered in 6 × 0.5 Gy) versus sham for mild–moderate knee OA. These presentations—summarized in ASTRO material and contemporary news coverage—suggest the field is evolving and that newer regimens or patient selection strategies may yield positive results; however, many of these reports are initially conference abstracts or press releases and require full peer-reviewed publication before they should change standards of care. (Kim,B. H. et al., 2025, ASTRO News Release).

 
To recapitulate, the older RCTs (hand and knee OA) did not show benefit over sham and therefore argue for caution; large observational series and long European experience support potential efficacy in practice; and very recent controlled data (2024–2025 conference reports) raise the possibility that particular doses, fractionations, or patient subgroups may benefit. The balance remains uncertain pending peer-reviewed publication and independent replication

Safety considerations
 

• Dose-relative risk: LDRT for OA uses doses that are a small fraction of oncologic therapy; nevertheless, any ionizing radiation carries theoretical carcinogenic potential. Epidemiologic and modeling studies suggest the absolute risk of radiation-induced malignancy from contemporary LDRT protocols is small, especially in older adults, but non-zero—risk is higher the younger the patient and the closer irradiated tissues are to radiosensitive organs or active bone marrow. Policy statements and reviews therefore emphasize individual risk–benefit assessment (McKeown, S. R. et al., 2015, Mazonakis, M. & Damilakis, J. 2017). 
• Short-term adverse events: Reported acute toxicities are uncommon and mild (transient skin erythema, fatigue). Serious immediate toxicity is rare at the low doses used for benign disease (Dove, A. P. H. et al., 2022).
• Long-term safety: Longitudinal data from large European cohorts show low absolute numbers of potentially radiation-related cancers after decades of follow-up, but uncertainty remains because long latency and confounding make precise risk quantification difficult. Expert guidance therefore typically recommends cautious use in patients <40 years of age, avoidance in pregnancy, and careful documentation and counseling about uncertain long-term risks. Professional bodies (radiation oncology and radiology colleges) advise that LDRT for benign disease be governed by local protocols and multidisciplinary oversight (van den Ende, C. H. M. et al., 2020, RCR Recommendation, 2023).
• Other practical cautions: avoid repeat courses unless clear benefit occurred previously and the risk–benefit remains favorable; consider proximity to major organs/bone marrow when planning fields; and ensure modern planning/beam-shaping techniques to minimize unnecessary exposure. (Dove, A. P. H. et al., 2022, DEGRO Guidelines for Radiotherapy of Benign Diseases, 2022)

Current Clinical Practice
 

• European practice: LDRT is an accepted, commonly used option for selected patients with painful OA and other degenerative musculoskeletal conditions in parts of Europe (notably Germany and Central Europe), often when conservative measures (exercise, weight loss, analgesics, injections) have failed or are contraindicated. (Weissmann, T. et al. ,2023, Wiśniowska, A. et al., 2025)
• North American practice: Historically LDRT was abandoned in the U.S.; renewed interest in specialized radiation oncology centers has grown only recently. Because of mixed RCT data and regulatory/coverage issues, LDRT is not yet a broadly endorsed standard in many North American guidelines. Emerging randomized evidence presented in 2025 may change practice if peer-reviewed reports confirm benefit and safety (Cleveland Clinic, 2023, Haelle, T., 2025).

​Conclusion
 
Evidence for LDRT includes decades of European experience and many observational studies showing pain relief, but two high-quality sham-controlled trials (hand and knee OA) found no benefit versus sham. More recently randomized data presented at meetings suggest certain modern schedules might be effective, but those reports await full peer review. The therapy uses doses far lower than cancer treatment and short-term side effects are uncommon. The principal long-term concern is a small but uncertain risk of radiation-related malignancy, particularly relevant for younger patients. Given this mixed evidence, LDRT would be considered only if the patient remains symptomatic despite guideline-based conservative care and understands the benefits and risks. A radiation oncology consultation will best address technical planning, expected timeline for benefit (often weeks to months), and follow-up.

US Radiology Centers offering LDRT
 
Reservation about LDRT notwithstanding, a quick non comprehensive search of the web yielded multiple clinical sites across the US offering the service for osteoarthritis and other non-malignant conditions:
 
UCLA Health Radiation Oncology (Los Angeles, California, and surrounding areas)
Loyola Medicine (Maywood, Illinois)
New York Cancer & Blood Specialists (NYC / metro NY)
Mount Sinai Health System (NYC)- Anthony Nehlsen MD, Radiation Oncology
Astera Cancer Care — Monroe Township, NJ
Hunterdon Regional Cancer Center (Hunterdon Healthcare), Flemington/Hunterdon County, NJ
RWJ Barnabas Health / Regional radiation oncology programs (NJ)
Allegheny Health Network (AHN) (Western Pennsylvania)
Radiation Oncology Services- Charleston Area Medical Center
Compass Oncology (Portland, Oregon, and Vancouver, Washington area)
Erlanger (Chattanooga, Tennessee area)
Mayo Clinic (Rochester, Minnesota area)
 
If you are interested in LDRT for osteoarthritis, consultation with your primary care doctor or specialists (rheumatologists, sport medicine practitioners) is a prerequisite before any action steps.

Introduction

There is a growing interest in how nutrition can improve health in the U.S., especially when it comes to using diet as an extra tool to support medical treatment. In this article, we will look at how plant-based eating can play a role in tackling major health challenges like heart disease and cancer. We’ll also touch on autoimmune conditions, which may not always be fatal but can affect quality of life and shorten lifespan.

We will explore what the research says about how plant-based diets might help prevent disease, support recovery, and promote long-term health. Just as important, we will look at clinical evidence to see whether these diets really make a difference in prevention and treatment.

​The potential benefits are clear when you compare plant-based diets with the typical Western diet, often high in refined carbs, sugar, and unhealthy fats but lacking in fiber, vitamins, and essential nutrients. Understanding these benefits is the first step in breaking through cultural habits that keep us tied to less healthy eating patterns. Still, not all plant-based diets are the same, so choosing and implementing them wisely is key to getting results.

Adequate Plant-Based Diet for Adult Health

Not all plant-based diets are created equal. Simply cutting out animal products doesn’t automatically make a diet healthy. A well-balanced, health-supporting plant-based diet focuses on whole, minimally processed foods from a variety of groups to ensure adults get the essential macronutrients and micronutrients needed for optimal physical and mental function.
Core components include:

• Vegetables – leafy greens, cruciferous veggies, and colorful varieties
• Legumes – lentils, beans, peas, chickpeas, soy
• Whole grains – oats, brown rice, quinoa, whole wheat
• Nuts and seeds – almonds, walnuts, chia, flax, hemp
• Fruits – berries, citrus, apples, and more
• Plant-based oils – extra-virgin olive oil, flaxseed oil
• Calcium-rich foods – fortified plant milks, tofu, leafy greens

​To be effective, these diets should align with U.S. dietary guidelines. Special attention is needed for nutrients that are sometimes harder to get from plants, such as protein, iodine, zinc, calcium, non-heme iron, omega-3 fatty acids, and vitamins D and B12. Supplements can help fill these gaps when necessary.

A practical example of a healthy plant-based eating pattern might include:

• 5 or more servings of vegetables and fruits per day
• 2 to 4 servings of whole grains daily
• 2 to 3 servings of legumes daily
• Plus, nuts or seeds, fortified plant milk, and a source of omega-3s (like flax or algae)
• With Vitamin B12 and Vitamin D supplements
• While limiting refined and ultra-processed foods

By contrast, a poor-quality plant-based diet is heavy on ultra-processed snacks or meat substitutes (like chips, vegan bacon, or sugary cereals), refined grains, and sweetened drinks. Diets that lack variety—relying mostly on pasta and fruit, for example—or that miss key nutrients like B12, omega-3s, or calcium are also inadequate and not health-promoting.
With a sound understanding of what makes plant-based nutrition truly supportive, we can now look at its role in managing cardiovascular disease, cancer, and autoimmune conditions. The evidence so far is promising, but it points to meaningful benefits rather than outright cures.

Cardiovascular Diseases and Plant-Based Nutrition

Plant-based diets support cardiovascular health through several key pathways. Most importantly, they improve major risk markers for cardiovascular disease (CVD), including:

• Better metabolic control – High fiber and plant sterols help regulate blood sugar, improve insulin sensitivity, and lower both blood pressure and body mass index (1-4).
• Improved cholesterol profile – Vegan and vegetarian diets, naturally low in saturated fat and cholesterol, reduce LDL-C, total cholesterol, and apolipoprotein B, thereby lowering atherosclerosis risk (1,2,4-7).
• Reduced inflammation – These diets are linked with lower levels of inflammatory markers such as CRP, IL-6, and TNF-α, suggesting a direct benefit on vascular inflammation (8).

​The anti-inflammatory effects may partly come from removing certain animal-derived compounds:

• Heme iron (abundant in red meat) can catalyze the formation of reactive oxygen species (ROS), which drive inflammation (9).
• Phosphatidylcholine (lecithin) and betaine, found in animal products, are metabolized by gut microbes into trimethylamine-N-oxide (TMAO), a compound strongly linked to vascular inflammation (10).

Beyond mechanisms, clinical evidence supports the real-world benefits of plant-based nutrition. Observational and interventional studies consistently show reduced incidence and mortality from CVD among those adhering to healthy plant-based diets. For example:

• Quek et al. (11) performed a meta-analysis using plant-based dietary index (PDI) scores to distinguish healthy (hPDI) from unhealthy (uPDI) diets. They found that higher adherence to plant-based eating was significantly associated with lower CVD risk and mortality, as measured by hazard ratios.
• Gan et al. (5) also applied the PDI framework and found that the strongest adherence to healthy plant-based diets correlated with lower risks of both CVD and coronary heart disease (CHD), though not with stroke.

Taken together, the evidence suggests that plant-based nutrition offers meaningful protection for cardiovascular health—not just through theory, but also through measurable outcomes in clinical studies.
 
CDC Dietary Recommendations for Heart Disease Prevention and Management

​The Centers for Disease Control and Prevention (CDC) does not provide strict treatment meal plans but does offer evidence-based guidance aimed at lowering cardiovascular disease (CVD) risk. These recommendations highlight eating patterns that have consistently been shown to improve heart health.

The CDC emphasizes three main points:

1. Eat a Variety of Nutrient-Dense Foods
   • Vegetables (especially leafy greens, cruciferous, and colorful varieties)
   • Fruits (whole fruits rather than juice)
   • Whole grains (brown rice, oats, quinoa, whole wheat)
   • Legumes (beans, lentils, peas)
   • Nuts and seeds (unsalted, raw, or dry roasted)
   • Lean protein (such as fish, skinless poultry, or plant-based proteins like tofu and tempeh)
2. Limit Foods That Increase CVD Risk
   • Saturated fat (from red meat, butter, cheese, and other full-fat dairy)
   • Trans fats (from partially hydrogenated oils — should be avoided entirely)
   • Sodium (keep under 2,300 mg per day; even lower if hypertensive)
   • Added sugars (limit to less than 10% of daily calories, ideally less)
   • Ultra-processed foods (packaged snacks, sugary drinks, processed meats)
3. Follow Proven Dietary Patterns
   • DASH Diet (Dietary Approaches to Stop Hypertension): Rich in fruits, vegetables, and whole grains, with reduced sodium and saturated fat.
   • Mediterranean Diet: Emphasizes olive oil, vegetables, legumes, fish, and nuts.
   • Vegetarian or Plant-Based Diets: When well-planned, these are linked to lower LDL cholesterol, blood pressure, and body mass index (BMI).

Web resources  provided by the CDC include the following:

• Preventing Heart Disease
• Healthy Eating Tips
• Healthy Eating Communications Kit

The American Heart Society and the Mayo Clinic also offer specific dietary guidance:

• The American Heart Association Diet and Lifestyle Recommendations

• Heart-healthy diet: 8 steps to prevent heart disease

Cancer and Plant-Based Nutrition

Cancer Liability in Meat Products

​The National Cancer Institute warns that meat cooked at high temperatures contains carcinogens—a caution that alone should encourage the public to limit or avoid meat, since most meat is typically cooked before consumption. Replacing cooked meat with plant-based alternatives can only benefit health.
The key carcinogens in cooked meat are heterocyclic amines (HCAs) and polycyclic aromatic hydrocarbons (PAHs):

• HCAs form when amino acids, sugars, creatine, and creatinine react at high temperatures (200–300°C).
• PAHs arise when fats drip onto hot surfaces or open flames, producing smoke that coats the meat or is inhaled nearby (12-14).

​Both HCAs and PAHs are mutagenic. They require activation by liver enzymes and form DNA adducts—a critical step toward chemical carcinogenesis (15-16).
Even uncooked meat carries cancer risks due to heme iron, the iron-containing complex found abundantly in hemoglobin and myoglobin. Heme iron is highly bioavailable and chemically reactive, participating in redox reactions that promote lipid peroxidation and potentially carcinogenic compounds. Key pathways include:

• Lipid oxidation: Heme iron reacts with hydrogen peroxide and lipid hydroperoxides to generate reactive oxygen species (ROS), triggering peroxidation of polyunsaturated fatty acids and producing cytotoxic aldehydes such as malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE), which can form DNA adducts (17-19).
• Endogenous formation of N-nitroso compounds (NOCs): Heme iron catalyzes nitrosation reactions between dietary nitrites/nitrates and amines or amides, producing nitrosamines and nitrosamides, potent DNA-alkylating agents (20-21). These compounds can form covalent DNA adducts, causing miscoding, strand breaks, and genomic instability—a hallmark of cancer initiation (22).

DNA adduct formation is a crucial early step in carcinogenesis. If adducts escape repair, permanent mutations can accumulate in oncogenes or tumor suppressor genes such as KRAS or TP53, promoting tumor development, especially in the colorectal epithelium (23-25).
Heme iron thus has a dual role: it provides nutritional value but also promotes oxidative stress and DNA-reactive compounds, explaining why high red and processed meat consumption is linked to cancer.

Potential Cancer Liability in Dairy Products

Milk and dairy products contain significant amounts of growth factors and sex hormones, which has raised concern among medical researchers because of their potential cancer-promoting effects (26-28).
IGF‑1

• Significant levels: Cow’s milk naturally contains IGF‑1 (insulin-like growth factor 1), typically around 4 ± 1 ng/mL in non-colostrum milk, with potentially higher levels when cows are treated with recombinant bovine somatotropin (rBST/rBGH). Bovine IGF‑1 is identical to human IGF‑1, resists pasteurization, and can remain intact in processed milk. Observational and intervention studies show that each 200 g/day increase in milk intake is associated with about a 10 µg/L rise in circulating IGF‑1 in adults, while cheese and yogurt show no such correlation.
• Potential risk: Elevated systemic IGF‑1 levels have been linked epidemiologically to higher risks of multiple cancers, including prostate (29-30), breast (28), endometrial (31), and colorectal cancer (32). A systematic review of 173 studies concluded that milk intake modestly increases circulating IGF‑1, and higher IGF‑1 levels correlate with elevated prostate cancer risk (33).

Estrone, estradiol, and progesterone

• Significant levels :Milk also contains measurable amounts of these steroid hormones, as most dairy cows used in production are pregnant. They are lipophilic hormones and remain in the fat fraction, so whole milk has higher concentrations than skimmed varieties.
• Potential risk :Steroid sex hormones in milk could theoretically stimulate the growth of hormone-dependent cancer cells. Experimental studies have shown that milk extracts can enhance the growth of prostate cancer cells in culture (34). Additionally, serum and urine levels of estrogen and progesterone derivatives rise significantly after consuming three to four cups of milk (35). Epidemiological data also link milk, dairy products, and dietary fats to breast (36-37, 28), endometrial (  31, 39), and prostate cancers (38, 29, 30).
• Controversy: Despite these associations, direct proof that steroid hormones in milk cause cancer is lacking. Experts remain divided: some argue that hormone levels in milk are minimal compared with endogenous production, so moderate consumption is unlikely to matter (40). Others consider the data still too conflicting to justify warnings (41-42).

Currently, neither the National Cancer Institute (NCI) nor the American Cancer Society (ACS) has issued formal advisories linking milk consumption to cancer. Other major organizations, including the American Institute for Cancer Research (AICR), Cancer Research UK, the British Dietetic Association, Cancer Council Australia, and the World Cancer Research Fund, share this position.

Protective Effects of Plant-Based Diets Pre- and Post-Cancer Diagnosis

Understanding the potential risks of meat and dairy for cancer is valuable, but it is even more important to know whether avoiding these foods and favoring vegetarian or vegan diets actually makes a difference. Evidence from observational and controlled studies suggests that it does.
A systematic review and meta-analysis of observational studies found that vegetarians and vegans enjoy lower overall cancer incidence among other health benefits (1).

Breast Cancer

• Lower mortality: For breast cancer specifically, adhering to a healthful plant-based diet (hPDI) after diagnosis was linked with reduced overall and non-breast cancer mortality, while an unhealthful plant-based diet (uPDI) increased mortality (43). In another study of 8,927 women with stage I–III breast cancer, higher consumption of vegetables—especially green leafy and cruciferous types—was associated with better survival. Notably, each two servings per week of blueberries corresponded to a 25% lower breast cancer-specific and 17% lower all-cause mortality (44).
• Lower risk: A case-control study in Connecticut found that higher intake of soluble plant fibers significantly reduced breast cancer risk in premenopausal women, particularly those with estrogen receptor-negative tumors. Postmenopausal women did not experience this protective effect (45).
• Protective effects of lignans and isoflavones: Other studies confirmed these findings (46-47) while highlighting the role of lignans—plant polyphenols with antioxidant and anti-estrogenic activity—in reducing both incidence and recurrence of breast cancer (48-51). Isoflavones from soy also show protective effects, reducing both incidence and improving survival after diagnosis (52-54).
• Endometrial cancer: The benefits of plant-based diets observed in breast cancer could also be demonstrated in endometrial cancer as well (55).

Prostate Cancer

• Improved oncologic outcomes: A systematic review and meta-analysis of multiple prostate cancer studies showed that patients adhering to a plant-based diet after diagnosis had improved oncologic outcomes. Patients  at-risk did not benefit as much since most studies showed lower incidence or no significant difference (56).
• Protective effects of lignans and isoflavones: As in breast cancer, the beneficial effect was traced to plant products rich in isoflavones and lignans. Randomized controlled studies showed that including soy isoflavones as part of a diet plan clearly reduced the incidence of prostate cancer (57). The finding was consistent with an earlier report describing high levels of isoflavonoids and lignans in the plasma and prostatic fluids of men originating from regions where the incidence of prostate cancer is low (58).
• Protective effects of flaxseeds & nuts: Additionally, it was demonstrated in controlled clinical studies that direct supplementation of the diet of prostate cancer patients with flaxseeds, a rich source of lignans and omega-3 fatty acids, for just 30 days could lower the proliferation rates of their tumors (59). Likewise, high consumption of nuts after diagnosis was associated with reduced overall mortality by as much as 34%, although no effect on incidence could be detected (60).

Gastric cancer

• Lower risk: A systemic review and meta-analysis found that patients adhering to “Prudent/Healthy” diets consisting of mostly fruits and vegetables with extra portion of fish, poultry and potatoes, had a two-fold less gastric cancer risk than those pursuing  “Western/unhealthy” diets, which lean heavily towards starchy foods, meat and fats (61).

Colorectal Cancer (CRC)

• Lower risk: Evidence for colorectal cancer is extensive. Healthy dietary patterns featuring whole grains, nuts, vegetables, legumes, fruits, seafood, and even dairy are consistently associated with lower CRC risk, while diets high in red and processed meat, refined grains, sugary drinks, and potatoes increase risk (62-64).
• Protective effects of fiber & flavonoids: In a very large study involving 2 million participants, legume fibers and flavonoids from soy beans were singled out as principal components of diets causing a decrease in CRC risk (65). These results were consistent with earlier studies, which also emphasized the importance of fibers from whole grains (66).
• Lower mortality after diagnosis: Consumption of quality plant-based food groups  after diagnosis was also beneficial for CRC patients. Recent systematic reviews and meta-analyses of clinical studies revealed a clear inverse relationship between healthy plant-based diets and all-cause mortality for CRC survivors (67-68). Plant components highlighted were fiber from cereals which were associated with both lower all-cause mortality and CRC-specific mortality whereas fiber from vegetables was only associated with lower all-cause mortality (69).
• Protective effect of nuts: Of particular interest were diets with higher consumption of nuts resulting in significantly reduced incidence of cancer recurrence and death in patients with stage III colon cancer (70).

Pancreatic Cancer

• Lower risk: It is among the deadliest forms of cancer, with one of the lowest survival rates. However, it may benefit from plant-based dietary approaches. Epidemiological studies have shown that higher consumption of fruits and vegetables is inversely associated with the risk of developing pancreatic cancer (71).
• Protective effect of fibers in wholegrains: Among various food groups, a high intake of whole grains has been specifically linked to a reduced incidence of the disease (72).
• No effect on survival after diagnosis: Despite these associations, there are currently no definitive studies or clinical trials demonstrating that plant-based diets or specific plant foods improve survival outcomes following pancreatic cancer diagnosis.

Lung Cancer

• Lower risk: Healthier, plant-forward diets—or higher intake of fruits and vegetables—are associated with a reduced risk of developing lung cancer (73)
• Improved survival: In contrast to pancreatic cancer, there is some observational evidence suggesting that, as well as improved overall survival in certain, though not all, cohorts of lung cancer patients (74).
• Effect on survival inconclusive: However, the evidence for a clear causal benefit of adopting a plant-based diet after a lung cancer diagnosis remains limited, heterogeneous, and inconclusive. To date, no large randomized controlled trials have demonstrated a definitive post-diagnosis survival advantage.

Overall, a well-planned plant-based diet—rich in vegetables, fruits, legumes, whole grains, nuts, flaxseed, and soy—can reduce cancer risk and support survival after diagnosis. While not a cure, these diets complement conventional treatment and align with evidence-based guidance for both prevention and survivorship.

CDC versus NCI, AICR & ACS: Positions on Nutrition and Cancer
​

• CDC: The Centers for Disease Control does not issue cancer-specific dietary guidelines for patients or individuals at higher risk. Instead, it offers general healthy eating recommendations aligned with broader public health goals, such as maintaining a healthy weight. For example, its Guide for Healthy Living for cancer survivors—particularly the section titled Cancer Survivors: Eating Healthy—encourages replacing some meat-based meals with vegetarian options, selecting canned or frozen fruits and vegetables that are low in salt and sugar, and seeking guidance from nutrition professionals or care teams.
• NCI: By contrast, the National Cancer Institute offers more targeted guidance for cancer patients, focusing on nutrition before, during, and after treatment through resources like Nutrition During Cancer Treatment.
• AICR: The American Institute for Cancer Research emphasizes cancer prevention, providing advice through Using Healthy Eating to Lower Cancer Risk, as well as programs for survivors like Coping with Cancer in the Kitchen  .
• ACS: The American Cancer Society delivers cancer-specific nutrition advice in its Guideline for Diet and Physical Activity, which summarizes a longer position paper published in CA: A Cancer Journal for Clinicians.

While the CDC takes a general approach, both the ACS and AICR provide more specific guidance for cancer prevention and survivorship. Interestingly, much of their advice—favoring vegetables, fruits, legumes, whole grains, nuts, and minimizing red and processed meats—closely aligns with the principles of a well-planned plant-based diet. This overlap reinforces the potential value of plant-based nutrition as part of a cancer-prevention and survivorship strategy, supporting both overall health and evidence-based dietary recommendations.

 
Autoimmune Diseases and Plant-Based Nutrition

Learning how to use nutrition to modulate the immune system is still in its early stages. Researchers are only beginning to understand how diet influences the distribution and function of immune cells in the body. Examples of dietary patterns that modulate the immune system include:

• Diets rich in chitin:  Fibers like chitin—found in mushrooms, crustaceans, and even edible insects—can stimulate type 2 immunity, which is normally involved in defense against parasites and allergic responses (75).
• Fasting:  It reduces circulating monocytes—immune cells that defend against invaders but are also central to many autoimmune diseases. Not surprisingly, fasting has been shown to improve conditions such as hypertension, atherosclerosis, diabetes, and asthma (76).
• Feasting: In contrast, feasting on low-fiber, high-fat diets rapidly impairs both gut and systemic immunity, leaving the body more vulnerable to bacterial infections (77, see also our blog post A balancing act: keeping your gut healthy).
• Clinical evidence: Importantly, these effects have been documented not only in laboratory experiments but also in clinical settings (78).

Clinical Evidence for Plant-Based Diets in Autoimmune Diseases

On a practical level, the key question is whether specific dietary interventions can reduce the risk of autoimmune diseases in the general population—or alleviate symptoms in patients already affected.

• Reduced risk: A growing body of observational studies links high consumption of plant-based foods with decreased risk in conditions such as multiple sclerosis (79), hypothyroidism (80), hyperthyroidism (81), and systemic lupus erythematosus (SLE) (82-83).
• Symptomatic improvement in rheumatoid arthritis: The first real attempt to test vegan diets as a treatment came in 1991, with a randomized, single-blind trial of 53 rheumatoid arthritis (RA) patients. After just four weeks, those on a vegan diet showed clear improvement in symptoms and biomarkers compared to controls, and many benefits lasted up to a year (84). These results were later supported by two small interventional trials (85-86) and more recently by a randomized cross-over study of 44 RA patients (87).
• Encouraging anecdotal reports in lupus nephritis: A case report of two patients with lupus nephritis found that switching to a raw, plant-based diet rich in leafy greens, cruciferous vegetables, omega-3 fatty acids, and water improved kidney function enough to avoid dialysis (88).
• Symptomatic improvement in SLE: In a cross-sectional study of 280 SLE patients, greater adherence to a Mediterranean diet—emphasizing plant-based over animal foods—was associated with reduced disease activity and cardiovascular risk (89). Another study of 420 SLE patients confirmed that eating more vegetables and fewer processed or animal-based foods correlated with less severe symptoms (90).
• Disease remission in SLE & Sjögren’s syndrome : Most recently, a case series of three patients with both SLE and Sjögren’s syndrome reported dramatic symptom improvements within just four weeks on a nutrient-rich, plant-based protocol (91).

​As promising as these reports are, they remain small in scale. Larger randomized controlled trials are still needed before plant-based nutrition can be established as a standard of care in autoimmune disease management. For now, adoption remains largely at the discretion of doctors and patients.

CDC vs. ACLM, ACR, and Harvard Positions
​

• CDC: It does not issue disease-specific diet guidelines for autoimmune conditions. Unlike its clearer recommendations for cardiovascular disease, diabetes, or obesity prevention, the CDC offers only general advice: eat a balanced diet rich in fruits, vegetables, and whole grains; choose lean proteins; and limit sodium, added sugars, saturated fats, and processed foods. These recommendations aim to reduce systemic inflammation, maintain a healthy weight, and support overall immune health. For conditions like lupus or RA, the CDC emphasizes calcium and vitamin D intake to counteract bone loss from corticosteroid treatment. It also lists autoimmune conditions under “chronic illnesses that weaken the immune system” in its guidance on safer food choices—even though in reality the immune system in these diseases is hyperactive against self-antigens, and often suppressed with immunosuppressive therapies.
• The American College of Lifestyle Medicine (ACLM) highlights plant-based nutrition in its guidance on Treatment and Prevention of Autoimmune Disease.
• The American College of Rheumatology (ACR) recommends the Mediterranean diet, with specific supplements & vitamins when necessary, for patients with rheumatic illnesses.
• The Harvard T.H. Chan School of Public Health and Harvard Health Publishing offer extensive resources on anti-inflammatory eating, including Foods That Fight Inflammation, Diet Review: Anti-Inflammatory Diet, and a Quick-Start Guide to an Anti-Inflammation Diet.

​Together, these organizations acknowledge what the research suggests: plant-forward diets can help reduce inflammation and improve quality of life in autoimmune patients, even if formal national guidelines lag behind the science.

Abstract
Pulsed electromagnetic fields (PEMF) and amplitude-modulated radiofrequency electromagnetic fields (AM-RF EMF) are emerging as non-invasive adjuncts in cancer therapy. Initially approved for bone healing and pain management, PEMF has shown potential in inhibiting tumor cell proliferation, inducing apoptosis, and impairing angiogenesis in various preclinical models. This review synthesizes findings from studies involving low- and high-intensity PEMF, tumor-treating alternating electric fields, and tumor-specific AM-RF EMF across cancer cell lines, animal models, and early-phase human trials. While results are promising, therapeutic responses remain highly context-dependent and mechanistically heterogeneous. Advances in structural biology and cancer genomics offer new opportunities to rationally design field parameters targeting specific molecular pathways. We propose a framework for estimating the electromagnetic field strength needed to disrupt key protein-ligand interactions and highlight pathways for future investigation. Rigorous clinical trials and optimized protocols will be essential to fully integrate PEMF into precision oncology.

Introduction
Pulsed Electromagnetic Field (PEMF) therapy is an FDA-approved, non-invasive modality widely used in orthopedics to support bone healing in conditions such as nonunion fractures, spinal fusions, and osteotomies. Devices like Orthofix’s Physio-Stim and Biomet’s EBI Bone Healing System deliver time-varying electromagnetic fields to stimulate cellular activity and promote osteogenesis and angiogenesis. These effects are mediated through mechanisms including modulation of ion binding, upregulation of growth factors (e.g., BMP-2, TGF-β), and increased expression of osteogenic markers (Bassett et al., 1974; Aaron et al., 2004).
Beyond orthopedics, PEMF is gaining attention as a complementary therapy for chronic pain, particularly musculoskeletal conditions such as osteoarthritis, fibromyalgia, and chronic low back pain. Although not FDA-approved for general pain relief, over-the-counter devices (e.g., Oska Pulse, BEMER) are marketed under Class I or II wellness exemptions. Studies suggest PEMF may reduce pain and improve function by modulating inflammation, nociceptive signaling, and microcirculation (Foley-Nolan et al., 1990; Thomas et al., 2007).
Emerging evidence now points to a potential role for PEMF in cancer therapy. Preclinical studies demonstrate that specific PEMF exposures can inhibit tumor cell proliferation, induce apoptosis, and impair angiogenesis in models of breast, lung, and brain cancers. Animal studies support these findings (Vadala et al., 2016), and early clinical trials suggest PEMF may improve quality of life and even exert direct antitumor effects in certain contexts (Zimmermann et al., 2012).
While clinical data are still limited, recent reviews emphasize the need for rigorous trials to optimize treatment protocols and clarify mechanisms (Xu et al., 2022, Egg & Kietzmann, 2025). This review examines key findings from cellular and animal studies, as well as preliminary human trials, tracing the evolution of this field from early research on alternating fields and modulated radiofrequencies to current interest in PEMF for cancer treatment.

Low and intermediate frequency alternating electromagnetic fields
Alternating electric fields in the intermediate frequency range (100–300 kHz) at field strengths of 1–2.5 V/cm (corresponding to magnetic fields of 0.44–1.1 μT) have been shown to suppress the proliferation of various rodent and human tumor cell lines—including Patricia C, U-118, U-87, H-1299, MDA231, PC3, B16F1, F-98, C-6, RG2, and CT-26—as well as malignant tumors in animal models. This inhibitory effect is both frequency- and intensity-dependent and is selective for actively dividing cells; non-proliferating (quiescent) cells remain unaffected. The mechanism of action of these tumor treating fields (TTFields) involves disruption of mitotic spindle formation, resulting in mitotic arrest and cell death (Kirson et al., 2004). These findings have been extended to additional cell lines (e.g., MDA-MB-231 and H1299) and tumor models (e.g., intradermal B16F1 melanoma and intracranial F-98 glioma). In a pilot clinical study of 10 glioblastoma patients, TTFields therapy more than doubled both median progression-free survival and overall survival compared to historical controls (Kirson et al., 2007).
In contrast, exposure of Caco-2 human colon adenocarcinoma cells to low-frequency (50 Hz), higher-intensity (1 mT) magnetic fields promoted cell growth rather than inhibiting it. This stimulation was time-dependent and accompanied by increased protein oxidation and elevated intracellular reactive oxygen species (ROS). These changes coincided with increased intracellular calcium levels and global activation of the 20S proteasome, along with a reduction in the pro-apoptotic protein p27 (Eleuteri et al., 2009).
Other studies have reported no significant effects of 1 mT, 60 Hz electromagnetic fields on non-cancerous immortalized cell lines such as Jurkat (human T lymphocytes) and NIH3T3 (mouse embryonic fibroblasts). However, under the same conditions, both MCF-7 (human breast cancer) and MCF-10A (non-tumorigenic breast epithelial) cells exhibited significant reductions in cell number, viability, and DNA synthesis. These effects were attributed to cell cycle delay and induction of the pro-apoptotic gene PMAIP in a context-dependent manner (Lee et al., 2015).
Overall, the biological effects of low- and intermediate-frequency EMFs on cancer cells are complex and highly context-dependent. Responses vary by cell type, proliferative status, field parameters (frequency and intensity), and exposure duration, underscoring the importance of precise characterization in therapeutic and experimental applications.

Amplitude modulated radiofrequency electromagnetic fields
In 2009, Barbault et al. reported that cancer patients exhibited biofeedback responses to tumor-specific frequencies of amplitude-modulated (AM) radiofrequency electromagnetic fields (RF-EMF). These modulation frequencies, ranging from 0.1 Hz to 114 kHz, were specific to the type of tumor, while the carrier frequency was a fixed 27.12 MHz. The RF signal was generated at 100 mW into a 50-ohm load. In a limited compassionate-use clinical trial involving 28 patients with various cancer types, RF-EMF treatment was delivered intrabuccally for 60 minutes, three times daily, and continued until disease progression or death.
No significant side effects were reported. Of the 13 patients eligible for response evaluation, one breast cancer patient achieved a complete response, and another showed a partial response. Four additional patients (with thyroid, lung, pancreatic cancers, and leiomyosarcoma) exhibited stable disease. The authors concluded that the observed clinical responses were more likely due to systemic physiological effects rather than direct cytotoxic action, given the low field strength and the anatomical distance between the intrabuccal application site and the tumor sites. Estimated field strengths within 1 mm of the emitter were approximately 30 V/cm (electric) and 13 μT (magnetic).
A subsequent open-label phase I/II clinical trial involving 41 patients with hepatocellular carcinoma (HCC) confirmed the earlier findings. Using the same protocol of tumor-specific AM RF-EMF delivery, 28 patients were evaluable for response: 4 demonstrated partial responses, 16 had stable disease, and 8 showed disease progression. These preliminary outcomes were considered promising and formed the rationale for pursuing larger, randomized clinical trials (Costa et al., 2011).
Follow-up mechanistic studies investigated the effects of tumor-specific modulation frequencies on HCC (HepG2, Huh7) and breast cancer (MCF-7) cell lines. Direct in vitro exposure resulted in significant growth inhibition of malignant cells, whereas non-malignant counterparts—THLE-2 hepatocytes and MCF-10A breast epithelial cells—were unaffected. Growth suppression in HCC cells was accompanied by downregulation of the chemokine-related genes XCL2 and PLP2, as well as disruption of mitotic spindle architecture. Notably, reduced expression of XCL2 and PLP2 has been associated with improved prognosis in cancer patients (Zimmerman et al., 2012).

Low intensity PEMF
The biological effects of pulsed electromagnetic fields (PEMF) on tumor cell growth have been recognized for over two decades. Early studies demonstrated that PEMF exposure at a magnetic field intensity of 1.5 mT and pulse frequencies of 1 or 25 Hz enhanced the cytotoxicity of chemotherapeutic agents—vincristine, mitomycin, and cisplatin—against multidrug-resistant HCA-2/1cch human colon adenocarcinoma cells in vitro (Ruiz-Gómez, M.J., 2002). At the same field intensity but a higher pulse frequency (75 Hz), PEMF upregulated A3 adenosine receptor (A3AR) expression in neural tumor cell lines, including PC12 (rat adrenal pheochromocytoma) and U87MG (human glioblastoma). This upregulation was associated with inhibition of NF-κB signaling and induction of p53, ultimately leading to suppressed proliferation, increased lactate dehydrogenase (LDH) release, and elevated caspase-3 activity—markers of cytotoxicity and apoptosis, respectively (Vincenzi, F., 2012). Similarly, growth inhibition and apoptotic induction were observed in the SKOV3 human ovarian cancer cell line following PEMF exposure at 1 mT with pulse frequencies ranging from 8 to 64 Hz (Wang et al., 2012).
More recent studies have extended these findings to other tumor types. In vitro and in vivo experiments involving human breast cancer MCF-7 cells and human lung adenocarcinoma A549 cells revealed that low-intensity PEMF (0.68 and 1.19 mT) applied at higher pulse frequencies (3.846 and 40.85 kHz, respectively) significantly inhibited tumor growth (Chen et al., 2022). This effect was attributed to increased apoptotic activity, evidenced by elevated caspase-3/7 expression and greater annexin V staining, as well as an accumulation of cells in the G0 phase of the cell cycle. Gene expression analysis further indicated activation of pathways associated with DNA damage, cell cycle arrest, and growth suppression.
Notably, the systemic impact of PEMF has also been demonstrated in humans. In a recent double-blind, randomized clinical trial involving healthy female volunteers, participants were exposed to PEMF at 1 mT intensity and 50 Hz pulse frequency (Iversen et al., 2025). Sera collected from treated individuals exhibited significant anti-cancer properties up to one month post-exposure, reducing breast cancer cell proliferation, migration, and invasiveness in vitro. These effects correlated with a reduction in epithelial-mesenchymal transition (EMT) markers, suggesting a systemic modulation of anti-tumor signaling pathways.

Higher intensity PEMF exposure
For the purposes of this review, high-intensity pulsed electromagnetic fields (PEMF) are defined as those with magnetic field strengths ranging from 2 to 400 mT, remaining within the public exposure limits recommended by the International Commission on Non-Ionizing Radiation Protection (ICNIRP) (Yamaguchi-Sakeno et al., 2011). The specific pulse frequencies and exposure durations varied across the studies discussed below.
Over the past two decades, a growing body of research involving both tumor cell lines and animal models has demonstrated that PEMF—either as a stand-alone treatment or in combination with chemotherapy or gamma irradiation—can exert antiproliferative and antiangiogenic effects. These studies typically used field intensities between 2 and 20 mT, pulse frequencies from 8 to 120 Hz, and diverse exposure regimens. Tumor types studied included breast, bladder, liver, hematopoietic cancers, osteosarcoma, and fibrosarcoma.
Breast cancer cell lines, particularly MCF-7, have shown notable sensitivity to PEMF. Exposure to PEMF at 3 mT and 20 Hz for 60 minutes daily over three days significantly inhibited proliferation (Crocetti et al., 2013). A separate protocol using full-square wave PEMF at 11 mT and 8 Hz, applied for 30 minutes twice daily over five days, yielded similar antiproliferative outcomes in both MCF-7 and MDA-MB-231 breast cancer cells (Pantelis et al., 2024). These effects were mechanistically linked to DNA damage, apoptosis, and the induction of cellular senescence markers. Importantly, these effects appeared to be selective for malignant cells; normal epithelial and fibroblast cells remained unaffected under the same treatment conditions.
The potential for PEMF to enhance chemotherapy has also been explored. In MCF-7 cells, PEMF exposure significantly potentiated the cytotoxic effects of doxorubicin (Woo & Kim, 2024) and etoposide (Woo et al., 2022). Both agents inhibit cell proliferation through topoisomerase II inhibition and reactive oxygen species (ROS) generation, and these pathways appeared to be further activated in the presence of PEMF.
Findings from in vitro studies have been validated in vivo. For example, PEMF exposure inhibited the growth and vascularization of 16/C murine mammary adenocarcinoma tumors implanted in syngeneic C3H/HeJ mice. Treatment consisted of 10-minute daily exposures for 12 days using a 120 Hz pulse frequency and field intensities up to 20 mT (Williams et al., 2001). Further studies confirmed that tumor inhibition was dependent on increasing magnetic field intensity rather than increased exposure time at a fixed intensity (Cameron et al., 2014). PEMF also enhanced the effects of gamma irradiation and the chemotherapeutic agent bleomycin in mouse models bearing human MDA-MB-231 breast cancer xenografts (Cameron et al., 2005) and triple-negative breast cancer (TNBC) MX-1 xenografts in SCID mice (Berg et al., 2010).
Beyond breast cancer, PEMF has demonstrated antitumor activity in models of bladder cancer (Sanberg et al., 2025), hematologic malignancies (Radeva & Berg, 2004; Berg et al., 2010), osteosarcoma (Muramatsu et al., 2017), and fibrosarcoma (Omote et al., 1990). Of particular interest is the reported synergy between PEMF and molecularly targeted therapies: in BCR/ABL(+) leukemia-derived TCC-S cells, PEMF enhanced the efficacy of the tyrosine kinase inhibitor imatinib (Yamaguchi-Sakeno et al., 2011).

Future directions
The growing body of evidence supports the continued development of pulsed electromagnetic fields (PEMF) as a complementary modality in cancer therapeutics. At present, PEMF demonstrates its greatest efficacy when combined with conventional treatments, such as cytotoxic chemotherapy or ionizing radiation. Several novel laboratory protocols have yielded promising results and merit translation into large-scale, double-blind clinical trials to evaluate therapeutic utility and safety in a controlled setting. However, current findings also highlight important areas for further refinement and optimization.
To date, no PEMF or EMF protocol has consistently achieved irreversible tumor regression as a stand-alone intervention. Moreover, the heterogeneity in field parameters—such as frequency, waveform, intensity, and exposure duration—across studies has impeded the establishment of a unified mechanism of action. Inhibition of cancer cell growth by PEMF appears to involve multiple, and potentially interacting, cellular processes, including alterations in membrane potential, disruption of mitochondrial function, interference with mitotic spindle formation, modulation of growth signaling pathways, increased generation of reactive oxygen species (ROS), and induction of apoptosis. While the preferential sensitivity of malignant cells compared to normal cells is encouraging, the underlying basis of this selectivity remains incompletely understood and warrants further mechanistic investigation.
Reliance on empirical trial-and-error testing may be inefficient and limiting, especially given current advances in cancer genomics and the characterization of key oncogenic driver mutations (Kinnersley et al., 2024). Moving forward, it would be advantageous to rationally design PEMF protocols that specifically disrupt molecular pathways activated by such driver genes. This approach could yield targeted, mechanism-informed applications of PEMF with improved therapeutic indices. Table 1 summarizes major classes of cancer-relevant signaling pathways and representative driver genes identified through high-throughput genome sequencing.
Many of the downstream effectors of cancer-associated gene products—such as enzymes, receptors, transcription factors, DNA-binding proteins, and scaffolding proteins—have had their structures experimentally determined and deposited in the Protein Data Bank (PDB), or accurately predicted by AlphaFold. This structural information provides a powerful foundation for estimating the electromagnetic field (EMF) intensities required to perturb or disrupt their functional interactions. In particular, these insights open the door to the rational design of PEMF protocols targeting specific molecular interactions central to tumor growth and survival.
Functionally disrupting a protein's activity via EMF can be conceptualized as interfering with its interactions with a substrate, ligand, DNA target, or binding partner. This disruption can occur if the energy imparted by the EMF is sufficient to overcome the standard free energy of binding (ΔG⁰), or alternatively, the free energy required to partially unfold one or both interacting molecules (ΔGᵤ).
For binding interference, the minimum energy supplied by the EMF must match or exceed the standard free energy of binding. On a per-molecule basis, this requirement can be written as:

E(emf) = (ΔG⁰/N)                   [1]

where N is the Avogadro number (6.022 x 1023 mol-1) since ΔG⁰ values are often given per mole.
The energy provided by an electric field (E) to a dipole or charge depends on the interaction between the field and the molecule dipole moment (μ​) or charge (q). For a dipole in an electric field, the potential energy (U) is the vectorial product of the electric field (E) and the dipole moment (μ), and maximum energy occurs when the dipole is aligned with the field and

U(max) = μE                                [2]

where μ is the magnitude of the dipole moment in Debyes or C.m, and E the electric field strength in V/m.
Since the energy required by the field to disrupt binding must at least be equal to the free binding energy,

μE = ΔG⁰/N                        [3]

Solving for E,

E = ΔG⁰/(Nμ)                      [4]

In practice, ΔG⁰ could be derived from the equilibrium binding constant Keq using,

ΔG⁰ = -RTlnKeq                  [5]

where R is the universal gas constant ( ≈ 8.314 J⋅mol⁻¹⋅K⁻¹) and T the temperature in Kelvin (K).
The corresponding magnetic field strength could be derived from,

B = E/c                                  [6]
​
 a consequence of Maxwell’s equations and where c is the speed of light (≈ 3 x 108 m/s).
Table 2 shows the calculated magnetic field intensities required for disrupting the functions of selected therapeutic targets in cancer pathways. These calculated values should be regarded as preliminary approximations, given several limitations in the underlying dipole moment estimations. Notably, solvent effects and electrostatic contributions from bound ligands were not included, even though they may significantly alter the net dipole moment of the complex. Despite these limitations, the estimates can serve as a useful starting point for the design of more targeted and effective pulsed electromagnetic field (PEMF) protocols—particularly with respect to field strength, pulse frequency, and exposure duration.
As discussed earlier, a complementary approach to estimating the required magnetic field intensity involves the use of the free energy of unfolding (ΔGᵤ) of the protein or protein-ligand complex. However, accurate ΔGᵤ values typically require differential scanning calorimetry (DSC) data, which remain sparse in the literature for many of the cancer-associated targets included in this analysis.
Table 2 indicates that, in most cases, the magnetic field strengths needed to interfere with key oncogenic pathways fall within the operational range of FDA-approved PEMF devices used for specific clinical indications. Furthermore, some PEMF systems marketed for general wellness are capable of producing high peak magnetic field intensities—up to 100 mT—though often at lower frequencies. Clinical experience in areas such as bone regeneration and pain control suggests that efficacy is not solely determined by maximum field strength. Rather, an optimized combination of intensity, frequency, pulse width, and duty cycle is likely required for therapeutic benefit.
Future advances in PEMF technology—guided by personalized cancer genomic data and supported by rigorous clinical trials—may help establish electromagnetic field modulation as a viable adjunct or alternative in cancer therapy. Such progress will be essential to gaining broader acceptance within the medical community and among the general public.

References
Aaron, R. K., Ciombor, D. M., & Simon, B. J. (2004). Treatment of nonunions with electric and electromagnetic fields. Clinical Orthopaedics and Related Research, (419), 21–29.
Bassett, C. A. L., Pawluk, R. J., & Pilla, A. A. (1974). Augmentation of bone repair by inductively coupled electromagnetic fields. Science, 184(4136), 575–577.
Foley-Nolan, D., Barry, C., Coughlan, R. J., et al. (1990). Pulsed high-frequency (27 MHz) electromagnetic therapy for persistent neck pain: a double-blind, placebo-controlled study of 20 patients. Orthopedics, 13(4), 445–451.
Thomas, A. W., Graham, K., Prato, F. S., et al. (2007). A randomized, double-blind, placebo-controlled clinical trial using a low-frequency magnetic field in the treatment of musculoskeletal chronic pain. Pain Research & Management, 12(4), 249–258.
Vadalà, M., Morales-Medina, J. C., Vallelunga, A., et al. (2016). Mechanisms and therapeutic effectiveness of pulsed electromagnetic field therapy in oncology. Cancer Medicine, 5(11):3128–3139.
Zimmermann, J. W., Pennison, M. J., Brezovich, I., et al. (2012). Cancer cell proliferation is inhibited by specific modulation frequencies. British Journal of Cancer, 106(2), 307–313.
Xu, W., Xie, X. Wu, H. et al. (2022). Pulsed electromagnetic therapy in cancer treatment: progress and outlook. View 3, 20220029.
Egg, M. & Kietzmann, T. (2025). Little strokes fell big oaks: The use of weak magnetic fields and reactive oxygen species to fight cancer. Redox Biology 79, 103483.
Kirson, E. D., Gurvich, Z., Schneiderman, R. et al.(2004). Disruption of Cancer Cell Replication by Alternating Electric Fields. Cancer Research 64, 3288–3295.
Kirson, E. D., Dbaly, V., Tovarys, F. et al. (2007). Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proceedings of the National Academy of Sciences 104, 10152–10157.
Eleuteri, A. M., Amici, M., Bonfili, L. et al. (2009). 50 Hz extremely low frequency electromagnetic fields (ELF-EMF) enhance protein carbonyl groups content in cancer cells: effects on proteasomal systems. Journal of Biomedicine and Biotechnology Article ID 834239.
Lee, H.C., Hong, M-N., Jung, S.H., et al. (2015). Effect of extremely low frequency magnetic fields on cell proliferation and gene expression. Bioelectromagnetics, 36: 506-516.
Barbault, A., Costa, F. P., Bottger, B. et al. (2009). Amplitude-modulated electromagnetic fields for the treatment of cancer: Discovery of tumor-specific frequencies and assessment of a novel therapeutic approach. Journal of Experimental & Clinical Cancer Research 28, 51.
Costa, F. P., de Oliveira, A. C., Meirelles, R. et al. (2011).Treatment of advanced hepatocellular carcinoma with very low levels of amplitude-modulated electromagnetic fields. British Journal of Cancer 105,640–648.
Zimmerman, J.W., Pennison, M.J., Brezovich, I. et al. (2012). Cancer cell proliferation is inhibited by specific modulation frequencies. British Journal of Cancer 106, 307–313.
Ruiz-Gómez, M.J., de la Peña, L., Prieto-Barcia, M.I., et al. (2002). Influence of 1 and 25 Hz, 1.5 mT magnetic fields on antitumor drug potency in a human adenocarcinoma cell line. Bioelectromagnetics 23, 578-525. https://doi.org/10.1002/bem.10054
Vincenzi, F., Targa, M., Corciulo, C., et al. (2012). The Anti-Tumor Effect of A3 Adenosine Receptors Is Potentiated by Pulsed Electromagnetic Fields in Cultured Neural Cancer Cells. PloS ONE 7, e39317. doi:10.1371/journal.pone.0039317
Wang, Q., Wu, W., Chen, X., et al. (2012). Effect of pulsed electromagnetic field with different frequencies on the proliferation, apoptosis, and migration of human ovarian cancer cells. Sheng wu yi xue Gong Cheng xue za zhi = Journal of Biomedical Engineering 29, 291-295. (Language:chinese)
Chen, M.Y., Li, J., Zhang, N., et al. (2022). In Vitro and in Vivo Study of the Effect of Osteogenic Pulsed Electromagnetic Fields on Breast and Lung Cancer Cells. Technology in Cancer Research & Treatment 21. doi:10.1177/15330338221124658
Iversen, J.N., Tai, Y.K., Jasmine, Yap, J.L.Y., et al. (2025). One Month of Brief Weekly Magnetic Field Therapy Enhances the Anticancer Potential of Female Human Sera: Randomized Double-Blind Pilot Study. Cells 14, 331. https://doi.org/10.3390/ cells14050331
Yamaguchi-Sakino, S., Sakino, M. & Ueno, S. (2011). Biological Effects of Electromagnetic Fields and Recently Updated Safety Guidelines for Strong Magnetic Fields. Magn. Reson. Med. Sci. 10, 1-10.  https://doi.org/10.2463/mrms.10.1
Pantelis, P., Theocharous, G., Veroutis, D., et al. (2024). Pulsed Electromagnetic Fields (PEMFs) Trigger Cell Death and Senescence in Cancer Cells. Int. J. Mol. Sci. 25, 2473. https://doi.org/ 10.3390/ijms25052473
Woo, S-H. & Kim, Y.S. (2024). Pulsed Electromagnetic Field Enhances Doxorubicin-induced Reduction in the Viability of MCF-7 Breast Cancer Cells. Korean J Clin Lab Sci. 56, 73-84.
Woo, S-H., Kim, B., Kim, S.H., et al. (2022). Pulsed electromagnetic field potentiates etoposide-induced MCF-7 cell death. BMB Rep. 55, 148-153. https://doi.org/10.5483/BMBRep.2022.55.3.119
Williams, C.D., Markov, M.S., Hardman, W.E. et al. (2001). Therapeutic Electromagnetic Field Effects on Angiogenesis and Tumor Growth. Anticancer Research 21, 3887-3892.
Cameron, I.L., Markov, M. and Hardman, W.E. (2014). Optimization of a therapeutic electromagnetic field (EMF) to retard breast cancer tumor growth and vascularity. Cancer Cell International 14,125. http://www.cancerci.com/content/14/1/125
Cameron, I.L., Sun, L-Z., Short, N. et al. (2005). Therapeutic Electromagnetic Field (TEMF) and gamma irradiation on human breast cancer xenograft growth, angiogenesis and metastasis. Cancer Cell International  5, 23. doi:10.1186/1475-2867-5-23
Berg, H., Gunther, B., Hilger, I. et al. (2010). Bioelectromagnetic Field Effects on Cancer Cells and Mice Tumors. Electromagnetic Biology and Medicine 29, 1–12. doi: 10.3109/15368371003776725
Sanberg, M., Whitman, W. Bissette, R. et al. (2025). Pulsed Electromagnetic Field Therapy Alters the Genomic Profile of Bladder Cancer Cell Line HT-1197. J. Pers. Med. 15, 143. https://doi.org/10.3390/ jpm15040143
Sanberg, M., Whitman, W., Ross, C.. et al. (2025). Pulsed electromagnetic field therapy's effect on bladder cancer cell line HT-1376. Journal of Clinical Oncology 42 (4, suppl.). https://doi.org/10.1200/JCO.2024.42.4_suppl.666
Radeva, M. and Berg, H. (2004). Differences in lethality between cancer cells and human lymphocytes caused by LF-electromagnetic fields. Bioelectromagnetics 25, 503-507. https://doi.org/10.1002/bem.20023
Muramatsu, Y., Matsui, T., Deie, M. et al. (2017). Pulsed Electromagnetic Field Stimulation Promotes Anti-cell Proliferative Activity in Doxorubicin-treated Mouse Osteosarcoma Cells. In vivo 31, 61-68. doi:10.21873/invivo.11026
Omote, Y., Hosokawa, M., Komatsumoto, M. et al. (1990). Treatment of experimental tumors with a combination of pulsing electromagnetic field and antitumor drug. Jpn. J. Cancer Res. 81, 956-961.
Kinnersley, B., Sud, A., Everall, A. et al. (2024). Analysis of 10,478 cancer genomes identifies candidate driver genes and opportunities for precision oncology. Nat Genet 56, 1868–1877. https://doi.org/10.1038/s41588-024-01785-9
John, J. Rensland, H., Schlichting, I. et al. (1993). Kinetic and Structural Analysis of the Mg2+-binding Site of the Guanine Nucleotide-binding Protein p21H-ras. J. Biol. Chem. 268, 923-929.
Tran, T.H., Chan, A.H., Young, L.C. et al. (2021). KRAS interaction with RAF1 RAS-binding domain and cysteine-rich domain provides insights into RAS-mediated RAF activation. Nat Commun 12, 1176 (2021). https://doi.org/10.1038/s41467-021-21422-x
Knight, Z.A. and Shokat, K.M. (2005). Features of Selective Kinase Inhibitors. Chemistry & Biology 12, 621 – 637. DOI: 10.1016/j.chembiol.2005.04.011
Bossi, R.T., Saccardo, M.B.,  Ardini, E. et al. (2010). Crystal Structures of Anaplastic Lymphoma Kinase in Complex with ATP competitive Inhibitors . Biochemistry 49, 6813–6825. DOI: 10.1021/bi1005514
Petrosino, M., Novak, L., Pasquo, A. et al. (2023).The complex impact of cancer-related missense mutations on the stability and on the biophysical and biochemical properties of MAPK1 and MAPK3 somatic variants. Hum Genomics 17, 95. https://doi.org/10.1186/s40246-023-00544-x
Maheshwari, S., Miller, M.S., O’Meally, R., et al. (2017). Kinetic and structural analyses reveal residues in phosphoinositide 3-kinase α that are critical for catalysis and substrate recognition. J. Biol. Chem. 292, 13541 – 13550. DOI: 10.1074/jbc.M116.772426
Thorsell A-G., Ekblad, T., Karlberg, T., et al. (2016). Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors. J Med Chem. Dec 21;60(4):1262–1271. doi: 10.1021/acs.jmedchem.6b00990

​Acknowledgement: The author thanks Bill Windsor for providing some of the literature cited in this review.

Dedication: To my brother Kiet, who in heaven will know why.

In our discussion on May 16, 2024, we explored the role of the gut microbiome in Parkinson’s disease (PD) and the potential of fecal microbiota transplants as a treatment. A recent development further underscores the gut-brain connection in PD.
 
Nishiwaki H. and colleagues at Nagoya University [1] conducted a meta-analysis of microbiome studies across multiple countries, alongside metabolomic analyses of fecal samples from PD patients. Their findings identified specific gut microbes linked to the disease and a resulting deficiency in riboflavin (vitamin B2) and biotin (vitamin B7). This discovery suggests a simple, yet potentially impactful intervention: B vitamin supplementation.
 
The authors stated:
"Supplementation of riboflavin and/or biotin is likely to be beneficial in a subset of Parkinson's disease patients, in which gut dysbiosis plays pivotal roles."
 
Their recommendation is rooted in existing research. Riboflavin has demonstrated therapeutic benefits in reducing oxidative stress, mitochondrial dysfunction, neuroinflammation, and glutamate excitotoxicity—all factors in PD pathogenesis [2]. Notably, high-dose riboflavin has been shown to improve motor function in PD patients [3].
 
Biotin, on the other hand, is known for its anti-inflammatory properties, with benefits observed in allergy relief, immune regulation, and inflammatory bowel disease [4]. In high doses, it has been proven effective in treating motor and visual impairments in multiple sclerosis [5,6]. However, clinical evidence supporting biotin’s role in alleviating PD symptoms is still lacking.
 
These findings highlight the growing understanding of the gut microbiome’s role in neurodegenerative diseases and open the door for further research into the potential of targeted nutritional interventions in PD management.
 
You could read an excellent review of Nishiwaki H. et al. paper by Sciencealert.com here:

Parkinson's Gut Bacteria Link Suggests an Unexpected, Simple Treatment
Health23 March 2025
ByTessa Koumoundouros

​References
 
[1] Nishiwaki, H., Ueyama, J., Ito, M. et al. Meta-analysis of shotgun sequencing of gut microbiota in Parkinson’s disease. npj Parkinsons Dis. 10, 106 (2024). https://doi.org/10.1038/s41531-024-00724-z
 
[2] Marashly, E. T. & Bohlega, S. A. Riboflavin Has Neuroprotective Potential: Focus on Parkinson’s Disease and Migraine. Front. Neurol. 8, 333 (2017).
 
[3] Coimbra, C. G. & Junqueira, V. B. High doses of riboflavin and the elimination of dietary red meat promote the recovery of some motor functions in Parkinson’s disease patients. Braz. J. Med. Biol. Res. 36, 1409–1417 (2003).
 
[4] Kuroishi, T. Regulation of immunological and inflammatory functions by biotin. Can. J. Physiol. Pharmacol. 93, 1091–1096 (2015).
 
[5] Sedel, F. et al. High doses of biotin in chronic progressive multiple sclerosis: a pilot study. Mult Scler Relat. Disord. 4, 159–169 (2015).
 
[6] Sedel, F., Bernard, D., Mock, D. M. & Tourbah, A. Targeting demyelination and virtual hypoxia with high-dose biotin as a treatment for progressive multiple sclerosis. Neuropharmacology 110, 644–653 (2016).

​Understanding body weight is more than just looking at a number on the scale. It’s about how our bodies process energy, store fat, and regulate key metabolic functions. In this presentation, we will explore why physical appearance alone can be misleading and why not all fat is created equal. We’ll distinguish between beneficial brown fat and harmful white fat and examine how fat distribution, whether an "apple" or "pear" body shape, affects overall health.
Metabolic syndrome is a growing concern because of its potential link to body weight and obesity in particular. We’ll break down its risk factors, including how the body handles glucose and fat metabolism. With the rise of GLP-1 agonists, new therapies are revolutionizing the treatment of type 2 diabetes and weight management. We’ll also discuss the harmful effects of high blood sugar, elevated cholesterol, and triglycerides, which contribute to serious conditions like cardiovascular diseases.
Additionally, we’ll dive into the fascinating relationship between gut microbiota and diet, uncovering its surprising impact on weight and metabolism. The presentation will conclude with practical recommendations for lifestyle changes and emerging therapeutic options that can help optimize metabolic health.
Access this presentation and gain a deeper understanding of the complex factors that shape body weight and metabolic wellness by clicking on the link below.

​In recent years, scientific advancements have brought the gut microbiome—a diverse community of trillions of microorganisms living in our digestive tract—into the spotlight. Research has shown that the health of our gut microbiota plays a pivotal role in nearly every aspect of our well-being, from immune function and digestion to mental health and the prevention of chronic diseases. When this delicate balance of microorganisms is disrupted—a condition known as dysbiosis—it can contribute to issues like obesity, diabetes, autoimmune disorders, and even mental health conditions like depression.
 
Despite this growing body of evidence, public awareness about gut health remains surprisingly low. Many doctors and patients overlook the importance of monitoring digestive health until symptoms become unavoidable, at which point reactive solutions—costly tests, medications, or invasive procedures—take precedence. This reactive approach misses an important opportunity: the power of prevention through awareness and simple habits.
 
One of the easiest ways to keep tabs on your gut health is also one of the least discussed: regularly inspecting the frequency, consistency, and appearance of your stools. While it might seem unpleasant, this small act of mindfulness could provide vital clues about your overall health and help detect imbalances before they spiral into bigger problems. In this blog, we’ll explore why stool inspection should be a routine part of your self-care toolkit and how this simple practice can empower you to take charge of your gut health—without the need for expensive interventions down the line.

​The characteristics of human stool—such as consistency, frequency, and composition—serve as valuable indicators of gastrointestinal (GI) health. Monitoring these attributes can provide insights into digestive function and the state of the gut microbiome. Here's a summary of the relevant scientific literature on the subject:
 
Frequency: Regularity in bowel movements is an important aspect of gut health. Studies suggest that having at least one bowel movement per day is associated with a healthy gut microbiome. Infrequent bowel movements can lead to the buildup of toxins and an increased risk of chronic diseases, while overly frequent movements are linked to liver damage. Maintaining a "Goldilocks zone" of bowel movement frequency—neither too few nor too many—is considered optimal for health. A study published in Cell Reports Medicine [1] found that bowel movement frequency significantly influences physiology and long-term health. The best outcomes were linked with passing stools once or twice a day. Irregular bowel movements, such as constipation or diarrhea, were associated with higher risks of infections and neurodegenerative conditions.
 
Consistency: The consistency of stool is also a critical factor. The Bristol Stool Chart categorizes stool into seven types, ranging from hard lumps (Type 1) to entirely liquid (Type 7). Types 3 and 4 are considered optimal, indicating well-formed stools that are easy to pass and a healthy balance of fiber and water in the diet [2], while Types 1 and 2 suggest constipation, and Types 5 through 7 are associated with diarrhea [3].
 
Gut microbial composition affects both consistency and frequency: The gut microbiome plays a crucial role in digestion and overall health. Stool consistency is closely linked to the richness and composition of the gut microbiota. Research indicates that variations in stool form correlate with differences in microbial communities within the GI tract. For instance, a study found that stool consistency is strongly associated with gut microbiota richness and composition, enterotypes, and bacterial growth rates [4]. Research has also shown that the composition of gut bacteria is also strongly linked to bowel movement frequency. Fiber-fermenting bacteria, associated with good health, thrive in individuals who have bowel movements once or twice daily. In contrast, those with constipation or diarrhea showed higher levels of bacteria associated with protein fermentation or upper gastrointestinal tract issues [5].
 
Diet Influences stool characteristics: Diet plays a crucial role in determining stool characteristics. High-fiber foods, such as whole grains, fruits, and vegetables, contribute to stool bulk and promote regular bowel movements. For example, consuming fiber-rich snacks like dried mangoes can aid in relieving constipation by adding bulk to the stool and supporting a healthy gut microbiome [6]. Additionally, certain foods have been identified to alleviate specific digestive symptoms. Asparagus, for instance, contains prebiotics that support beneficial gut bacteria and can help reduce bloating [7].

​Toxins and Inflammation: When stools linger too long in the gut, microbes exhaust the available fiber and instead ferment proteins, producing toxins like p-cresol sulfate and indoxyl sulfate. These toxins can enter the bloodstream and burden the kidneys [1]. On the other hand, diarrhea can lead to excessive bile acid excretion, causing inflammation and liver damage [1].
 
Chronic Disease: Chronic constipation has been associated with neurodegenerative disorders and chronic kidney disease progression. However, it remains unclear whether bowel movement abnormalities are early drivers of chronic disease or merely coincidental [5].
 
Monitoring stool characteristics provides valuable insights into gut health. Maintaining optimal stool consistency and regularity through a balanced diet rich in fiber, adequate hydration, and regular physical activity can support a healthy digestive system and promote overall well-being.

​Frequency
 

• Ideally 1-2 bowel movements a day, as discussed above.
• 2-3 bowel movements a week is still considered normal, if the individual is properly hydrated, has a diet adequately rich in fibers, and has adequate level of exercise.
• Lifestyle changes and/or medical intervention would be appropriate if outside of this range

 
Consistency
 
Type 3 or 4 is considered normal, as shown in Bristol Stool Form Scale below:

[Reproduced from Wikipedia: Bristol stool scale]
 Lifestyle changes and/or medical intervention would be appropriate if outside of this range

​The color of your stool is also an important yet often overlooked indicator of your digestive and overall health. While stools are typically various shades of brown due to bile pigments, they can undergo temporary changes based on diet, medications, and supplements. However, persistent or unusual stool discoloration can sometimes signal underlying health concerns that require medical attention [1-3].
 
Common Causes of Stool Discoloration
 
1.Dietary Influences

• Green stools: Commonly caused by eating large amounts of leafy greens (e.g., spinach, kale) or green food dyes. Rapid transit through the gut can also prevent bile from fully breaking down, leading to greenish stools.
• Red stools: Beets, tomatoes, cranberries, and artificially colored foods can give stools a reddish hue. However, it is essential to differentiate between food-related changes and the presence of blood.
• Yellow or greasy stools: High-fat meals, malabsorption disorders (such as celiac disease), or excessive intake of foods like turmeric can lead to yellowish stools.

 
2.Medications, Vitamins, and Supplements

• Iron supplements and bismuth-containing medications (e.g., Pepto-Bismol) can cause black stools.
• Certain antibiotics and antacids may contribute to lighter or clay-colored stools.
• Vitamin supplements with high doses of beta-carotene (from carrots or sweet potatoes) can sometimes result in orange-hued stools.

 
When Should You Be Concerned?
 
While many changes in stool color are harmless and temporary, certain discolorations warrant medical attention:

• Bright red stools: If not explained by diet (e.g., beets), this may indicate lower GI bleeding from hemorrhoids, diverticulosis, or more serious conditions like colorectal cancer.
• Black or tarry stools (melena): This could be a sign of upper GI bleeding from ulcers, gastritis, or esophageal varices.
• Pale, clay-colored stools: A lack of bile pigments could suggest bile duct obstruction, liver disease, or gallbladder dysfunction.
• Yellow, greasy, foul-smelling stools: This may indicate fat malabsorption, often linked to pancreatic insufficiency, celiac disease, or other digestive disorders.

 
Being mindful of stool color can provide important clues about gut health. While most changes are benign and linked to diet or supplements, persistent abnormalities—especially those accompanied by other symptoms like pain, weight loss, or fatigue—should prompt further medical evaluation. A simple daily glance at your stool could be a key step in proactive health monitoring, helping you catch potential issues before they become serious.

​In current medical practice, managing pain often means reaching for a pill bottle. While medications like aspirin, non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and opioids can be effective in alleviating pain, they also come with a host of potential side effects. Long-term use of NSAIDs, for instance, may lead to gastrointestinal issues, kidney damage, and increased cardiovascular risk [1]. Steroidal anti-inflammatory drugs can suppress the immune system and contribute to osteoporosis [2], while opioids carry a well-documented risk of dependency and addiction [3]. Despite these risks, society continues to lean heavily on pharmaceuticals as the primary solution for pain management.
 
Growing awareness of side effects has led many to seek non-drug alternatives. Techniques such as physical therapy, acupuncture, mindfulness meditation, and dietary changes are gaining traction for their ability to reduce pain and improve quality of life without the risks associated with medication [4]. Among these alternatives, the use of electromagnetic stimulation has emerged as a particularly intriguing option. Devices like Transcutaneous Electrical Nerve Stimulation (TENS) units and Pulsed Electromagnetic Field (PEMF) therapy are becoming more popular for their potential to manage pain in a non-invasive and drug-free manner [5,6]. The National Center for Complementary and Integrative Health (NCCIH) provides a public fact sheet on using magnetic fields for pain management [7].
 
This blog will focus specifically on Pulsed Electromagnetic Field (PEMF) therapy, exploring how it works, its applications in pain management, and the scientific evidence supporting its use. Whether you are seeking a complementary approach to traditional treatments or an alternative to medications, PEMF therapy may offer a promising solution. Let us dive in to understand more about this innovative technology and its role in pain relief.

Distinction between static and pulsed magnetic fields: Both modalities are based on the interaction between magnetic fields and biological systems, with the objective of promoting healing, alleviating pain, and enhancing cellular function. However, there are fundamental distinctions affecting their effectiveness.
 
Static magnetic therapy (SMT) involves the use of magnets that produce a constant, unchanging magnetic field. Magnets are usually embedded in bracelets, insoles, or pads and placed on or near the body. The steady magnetic field influences the alignment of charged particles in tissues and potentially affects ion exchange processes across cell membranes. In SMT, the dose is quantified by measuring the magnetic flux density, which is typically expressed in units of Gauss (G) or Tesla (T). Most therapeutic magnets have a flux density ranging from 300 to 5000 Gauss. The depth of penetration and the effectiveness of the therapy depend on the strength of the magnet and the distance from the tissue being treated. However, definitive clinical evidence supporting SMT remains limited, with studies often yielding inconclusive or modest results.
 
Pulsed electromagnetic field, by contrast, employs time-varying magnetic fields generated by electrical currents passing through coils. These magnetic fields can penetrate deeper into the body and induce electric currents within tissues, stimulating cellular activity. The dosing in PEMF therapy is multifaceted and involves parameters such as:
 
1.Types of frequencies: the field frequency (also known as carrier frequency) within the pulse, and the pulse repetition frequency itself. The latter depending on applications could vary from a few Hz to several hundreds. The field frequency on the other hand, is usually several orders of magnitude higher, in the kHz or even MHz range.

2. Wave form: The shape of the electromagnetic pulse (e.g., sinusoidal, square, or sawtooth), which may influence the biological response.

3.Intensity: The strength of the magnetic field, measured in Gauss or Tesla, which varies depending on the therapeutic application.
​
4.Duration: The length of time the field is applied, often ranging from minutes to hours per session.

PEMF influences tissues through magnetic and induced electrical fields, causing movement of ions and charged particles. Over many years of research, there is consensus that low field frequency may be more bioactive than static fields, and pulsed fields could be more effective than continuous ones. Higher pulse frequencies and magnetic flux densities lead to stronger cellular responses, especially with repeated applications over more than 10 days. When information on wave forms is available, triangle wave forms show the highest cellular response. A meta-analysis of ninety-two studies found that PEMF effects vary by cell type and origin, with osteosarcoma cells being particularly sensitive [1]. The lack of standardization in study designs and documentation, especially the documentation of wave forms and pulse duration, tends to obscure the analyses PEMF data across studies. Overcoming these caveats will improve comparisons and replications and advance the pace of research.
 
The exact mechanisms by which magnetic fields exert therapeutic effects remain a topic of research. Hypotheses include the modulation of cell membrane ion channels and receptors, especially the adenosine receptors. As a result, PEMF affects many cellular processes including apoptosis, proliferation and differentiation of osteoclasts, mesenchymal stem cells, adipose-derived stem cells and tendon stem progenitor cells. On the overall, PEMF enhances microcirculation, and stimulates cellular repair processes, not only in bone, cartilage, and tendon tissues, but in the brain as well [2].

PEMF therapy has garnered over the decades robust evidence in clinical trials resulting in six FDA approvals for the following indications:
 
1.Therapy for non-union fractures, which are fractures that fail to heal properly (1979).
2.Adjunct therapy for post operative edema and pain (1987)
3.Urinary Incontinence and Muscle Stimulation (1998).
4.Adjunct therapy to Cervical Fusion Surgery in patients at elevated risk for non-fusion (2004).
5.Therapy for depression and anxiety (2006).
6.Therapy for the treatment of brain cancer (2011).
 
Additional FDA approvals are expected in the future since clinical trials based on PEMF intervention are still on-going. A review of clinicaltrials.gov indicated that to date 150 trials are registered addressing a wide range of conditions, mostly musculoskeletal disorders, neuropathies, neurological disorders, autoimmune and metabolic diseases.

​FDA approvals notwithstanding, the National Center for Complementary and Integrative Health (NCCIH) also listed PEMF therapy as potentially effective for the following conditions:
 

• Osteoarthritis
• Low back pain
• Complex Regional Pain Syndrome
• Menstrual pain
• Multiple Sclerosis and paresthesia pain

 
These recommendations are based on reviews of clinical reports up to 2021.

​Pulsed Electromagnetic Field (PEMF) therapy has gained popularity as a therapeutic tool for pain management, but like any treatment, it is essential to understand its safety and potential side effects. It is considered safe for most people as PEMF devices and associated protocols for medical applications operate below the exposure limits set by the International Commission on Non-Ionizing Radiation [1,2]. However, some individuals may experience mild and temporary side effects [3,4], such as:
 

• Tingling, warmth, or slight redness at the application site.
• Mild headaches, fatigue, or nausea.
• Temporary changes in sleep patterns.

 
These side effects are usually short-lived and often subside as the body adjusts to the therapy. It is important to listen to your body and consult with a healthcare provider if you experience any significant side effects.
 
PEMF therapy is not recommended for certain individuals [5], including:
 

• Pregnant women: Due to limited research on the effects of PEMF on fetal development.
• Organ transplant recipients: PEMF may interfere with immunosuppressant drugs.
• Individuals with implanted medical devices: Such as pacemakers or defibrillators, as PEMF can interfere with their functioning.
• People with magnetic or ferromagnetic implants: Or those deemed unsafe for MRI.
• Individuals with bleeding disorders: Or those taking blood-thinning medications.
• People with undiagnosed health concerns: It is crucial to consult a doctor before using PEMF.

 
It is always best to consult with a healthcare provider before starting any new therapy to ensure it's appropriate for your specific health needs.

Individuals considering PEMF therapy for pain management have several options: seeing a qualified professional, seeking special treatment centers, or trying the self-help path.
 
Seeing a doctor: The following healthcare professionals are more likely to be practitioners of PEMF therapy:
 

• Orthopedic Surgeons: Specialists in bone and joint health.
• Chiropractors: Often use PEMF therapy as part of their treatment plans.
• Pain Management Specialists: Focus on treating chronic pain conditions.
• Sports Medicine Doctors: Use PEMF therapy to aid in the recovery of sports-related injuries.

 
You can find PEMF therapy doctors through resources like WebMD and the Association of PEMF Practitioners (AOPP)
 
Special Treatment Centers: There are specialized centers that offer PEMF therapy, often as part of a broader range of integrative and regenerative treatments. Some notable ones include:
 

• Pulse PEMF Centers: These centers are certified and offer professional PEMF therapy. You can find a location near you using their location map.
• The Osteopathic Center: Offers PEMF therapy along with other integrative treatments. They have locations in Miami, Knoxville, Jupiter, and Jacksonville. More details can be found on their website.
• Health Mat Review Directory: Lists over 580 locations across the USA where PEMF therapy is available. You can find a practitioner near you using their directory.

 
Self-Help Devices and Operating Procedures: If you prefer to use PEMF therapy at home, there are several devices available for direct consumer purchase. Some selected options include:
 
Oxford Medical Instruments (OMI) offers an entire range of devices for spot and whole-body treatment
DC Cure PEMF Therapeutic Device offers a specialized product for low back pain.
Sota Magnetic Pulser is small affordable and portable device for spot treatment
 
Many others are compared and reviewed at health-related websites: Healthline, HealthNews, PMEF Therapy Hub and Medical News Today. PEMF therapy can be a versatile and effective treatment option for various conditions. Whether you choose to see a doctor, visit a specialized center, or use a self-help device, it's important to consult with a healthcare professional to determine the best approach for your specific needs.

I was introduced to PEMF therapy while visiting a patient in Switzerland, terminally ill with liver cancer and who used it extensively for relief of abdominal pain. During the visit I happened to mention annoying neck pain following the long overnight cross Atlantic flight. My neck pain tends to be recurrent because of poor posture during sleep and lasts two to three days before subsiding. The patient offered PEMF treatment by his device, for which I had little information, except that it was powerful and expensive. It was made in Germany and cost the equivalent of $8000. The duration of treatment would only be half an hour with a wand applied directly to the site of pain. I took the offer and to my astonishment the pain felt much better just 12 hours after treatment.
 
Returning home and upon much reflection, I decided to try PEMF therapy but not necessarily with an expensive and powerful device. I opted instead for the Sota Magnetic Pulser, Model MP6 (shown below), purchased from Amazon in 2020 for $395 excluding tax and shipping.

​The device comes with a wand for spot application. It could be used in two modes with the following output specifications:

​I uniquely used the regular mode to obtain relief within 12-24 hours not only for neck pain, but for other ailments including:
 

• Sciatic nerve pain by applying the wand directly onto the lumbar and lower buttock area of the leg involved.
• Minor sporting injuries like back-shoulder and muscle pain following a long session of archery practice, and knee pain following a long hike uphill.

 
PEMF therapy with the Sota Magnetic Pulser was effective for my case. Irrespective of its mechanism of action, my quality of life has been better since its purchase in 2020.